<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Olanzapine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Olanzapine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Olanzapine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10921" href="/d/html/10921.html" rel="external">see "Olanzapine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16033" href="/d/html/16033.html" rel="external">see "Olanzapine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709177"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration, 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients between 1.6 and 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5%, compared with a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patient is not clear. Olanzapine is not approved for treatment of patients with dementia-related psychosis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Postinjection delirium/sedation syndrome (Zyprexa Relprevv): </span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Adverse reactions with signs and symptoms consistent with olanzapine overdose, in particular, sedation (including coma) and/or delirium, have been reported following injections of olanzapine extended release (ER). Olanzapine ER must be administered in a registered health care facility with ready access to emergency response services. After each injection, patients must be observed at the health care facility by a health care provider for at least 3 hours. Because of this risk, olanzapine ER is available only through a restricted distribution program called Zyprexa Relprevv Patient Care Program, and requires health care provider, health care facility, patient, and pharmacy enrollment.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26715078"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ZyPREXA;</li>
<li>ZyPREXA Relprevv;</li>
<li>ZyPREXA Zydis</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867741"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT OLANZapine ODT [DSC];</li>
<li>AG-Olanzapine FC;</li>
<li>APO-OLANZapine;</li>
<li>APO-OLANZapine ODT;</li>
<li>Auro-Olanzapine ODT;</li>
<li>JAMP OLANZapine FC;</li>
<li>JAMP OLANZapine ODT;</li>
<li>Mar-OLANZapine ODT [DSC];</li>
<li>Mint-Olanzapine;</li>
<li>MINT-OLANZapine ODT;</li>
<li>PMS-OLANZapine;</li>
<li>PMS-OLANZapine ODT;</li>
<li>RAN-OLANZapine ODT;</li>
<li>RIVA-OLANZapine;</li>
<li>RIVA-OLANZapine ODT [DSC];</li>
<li>SANDOZ OLANZapine;</li>
<li>SANDOZ OLANZapine ODT;</li>
<li>TEVA-OLANZapine;</li>
<li>ZyPREXA;</li>
<li>ZyPREXA Zydis</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F203198"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimanic Agent;</li>
<li>
                        Second Generation (Atypical) Antipsychotic</li></ul></div>
<div class="block doa drugH1Div" id="F203161"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> A low starting dose (eg, 2.5 mg) and more gradual titration may be better tolerated in patients who are medically ill, at risk for postural hypotension, or may metabolize more slowly (eg, nonsmoking, female, ≥65 years of age). Due to the drug's sedating effect, bedtime dosing is preferred; alternatively, divided doses may improve tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jibson.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jibson.2019'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21dde351-f095-4a55-8b49-bf5298b1e8e6">Agitation/Aggression associated with psychiatric disorders, substance intoxication, or other organic causes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia, bipolar disorder) (labeled use), substance intoxications (off-label use), or other organic causes (off-label use)<b>:</b> Note: </b>Antipsychotics are appropriate when psychosis is suspected to be the primary cause of agitation/aggression. Avoid in suspected or confirmed intoxications with anticholinergic substances; other agents are used preferentially in some intoxications (eg, stimulants) or alcohol withdrawal. Depending on presentation, may combine oral administration with a benzodiazepine; parenteral administration with a benzodiazepine is not recommended due to risk of respiratory depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29885904','lexi-content-ref-Moore.2020','lexi-content-ref-22834451','lexi-content-ref-21601409','lexi-content-ref-22461918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29885904','lexi-content-ref-Moore.2020','lexi-content-ref-22834451','lexi-content-ref-21601409','lexi-content-ref-22461918'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Short-acting injection: Initial: 5 to 10 mg; may repeat based on response and tolerability 2 hours after initial dose and 4 hours after second dose; maximum: 30 mg/day (including oral olanzapine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22461918','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22461918','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral (off-label route):</b> Initial: 5 to 10 mg; may repeat based on response and tolerability every 2 hours up to 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22461918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22461918'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Short-acting injection (alternative agent) (off-label route): <b>Note:</b> IM administration is preferred in most clinical situations. If IV administration is used, limit to settings where patients can be closely monitored for respiratory depression (eg, emergency department) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22981685','lexi-content-ref-27823873','lexi-content-ref-30758221','lexi-content-ref-26720055','lexi-content-ref-27745766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22981685','lexi-content-ref-27823873','lexi-content-ref-30758221','lexi-content-ref-26720055','lexi-content-ref-27745766'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 5 to 10 mg single dose; if needed, may repeat once with an additional 2.5 to 5 mg dose ≥10 minutes after initial dose based on response and tolerability; total maximum dose: 10 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27823873','lexi-content-ref-26720055','lexi-content-ref-27745766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27823873','lexi-content-ref-26720055','lexi-content-ref-27745766'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b86ae9af-0983-405b-8c0b-a20590d54c4c">Agitation/Aggression and psychosis associated with dementia, severe or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression and psychosis associated with dementia, severe or refractory (alternative agent) (off-label use): Note:</b> Patients with dementia with Lewy bodies are at increased risk for severe adverse reactions; caution is required even with low doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Short-acting injection: Initial dose: 2.5 or 5 mg; may repeat based on response and tolerability with up to 2 additional 1.25 to 5 mg doses at intervals ≥2 hours after the initial dose and ≥1 hour after the second dose; maximum: 12.5 mg per episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11927174']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11927174'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 mg once daily, may increase dose based on response and tolerability in increments of 2.5 to 5 mg/day at intervals ≥1 week up to 10 mg/day (De Deyn 2004; Street 2000; Verhey 2006). In patients without a clinically significant response after an adequate trial (eg, up to 4 weeks), taper and withdraw therapy. Only continue in patients with demonstrated benefit; attempt to taper and withdraw at regular intervals (eg, within 4 months of initiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2be5d1b7-1f22-43b5-ba05-d622b2fdec4a">Anorexia nervosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anorexia nervosa (off-label use): Note:</b> For acutely ill patients who do not gain weight with nutritional rehabilitation plus psychotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Walsh.2019','lexi-content-ref-21961502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Walsh.2019','lexi-content-ref-21961502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 mg once daily; may increase dose based on response and tolerability in increments of 2.5 mg every 1 to 2 weeks up to 10 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21426603','lexi-content-ref-30654643','lexi-content-ref-18558642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21426603','lexi-content-ref-30654643','lexi-content-ref-18558642'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute mania, acute episodes with mixed features (labeled use), and acute hypomania (off-label use) (monotherapy or adjunctive therapy):</b> Oral: Initial: 10 to 15 mg once daily; may increase dose based on response and tolerability in 5 mg increments at intervals of ≥1 day up to 20 mg/day (maximum per manufacturer's labeling); however, experts suggest some patients may require doses up to 50 mg/day for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616','lexi-content-ref-19589053','lexi-content-ref-Stovall.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616','lexi-content-ref-19589053','lexi-content-ref-Stovall.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bipolar major depression, acute (alternative agent; monotherapy or adjunctive therapy) (off-label, except labeled use as adjunctive to fluoxetine):</b>
<b>Oral:</b> Initial: 5 mg once daily; may increase dose based on response and tolerability in 5 mg increments at intervals of every 1 to 7 days up to 15 mg/day (adjunctive therapy) or up to 20 mg/day (monotherapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16889444','lexi-content-ref-Shelton.2019','lexi-content-ref-22918966','lexi-content-ref-14609883','lexi-content-ref-24481570','lexi-content-ref-20148751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16889444','lexi-content-ref-Shelton.2019','lexi-content-ref-22918966','lexi-content-ref-14609883','lexi-content-ref-24481570','lexi-content-ref-20148751'])">Ref</a></span>). A fixed-dose olanzapine/fluoxetine combination may be used instead of separate components. See “Dosing Conversion” below.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance treatment (monotherapy [labeled use for mania or episodes with mixed features; off-label use for depression episodes] or adjunctive therapy [off-label use]): Note:</b> Continue dose and combination regimen that was used to achieve control of the acute episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Usual dose: 5 to 20 mg/day; maximum dose: 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); however, for patients who required doses up to 50 mg/day to achieve remission, continue remission-achieving dose, as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b54c3ae-cf44-47cd-a6ad-d2234fa97e0d">Chemotherapy-induced acute and delayed nausea or vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced acute and delayed nausea or vomiting (high emetic risk [&gt;90%]), prevention (off-label use):</b>
<b>Oral:</b> 5 or 10 mg on day of chemotherapy (day 1), followed by 5 or 10 mg once daily on days 2 to 4, in combination with antiemetics used for high emetic risk agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31838011','lexi-content-ref-22024310','lexi-content-ref-27410922','lexi-content-ref-30246876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31838011','lexi-content-ref-22024310','lexi-content-ref-27410922','lexi-content-ref-30246876'])">Ref</a></span>). For cisplatin-based high emetic-risk therapy, the 5 mg dose (in combination with triplet antiemetic therapy) is effective and may be associated with less daytime sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31838011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31838011'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9c5d5af-7e08-41cb-84e3-7a8c99bd2f2d">Chemotherapy-induced breakthrough nausea or vomiting, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced breakthrough nausea or vomiting, treatment (off-label use):</b>
<b>Oral:</b> 5 to 10 mg once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23314603','lexi-content-ref-30246876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23314603','lexi-content-ref-30246876'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe1ae4e5-73fd-4d98-85e5-a6c136ba052d">Delirium, hyperactive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delirium, hyperactive (treatment): Note:</b> Nonpharmacologic interventions and treatment of underlying conditions are initial steps to prevent and manage delirium. Antipsychotics may be used as short-term adjunctive treatment if distressing symptoms (eg, agitation, anxiety, combative behavior) are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>). Reassess daily for continued need; consider discontinuation and/or taper as symptoms resolve, especially at transitions of care to prevent unnecessary continuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28049388','lexi-content-ref-26818629','lexi-content-ref-Tietze.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28049388','lexi-content-ref-26818629','lexi-content-ref-Tietze.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ICU (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral or via NG tube:</b> Initial: 5 to 10 mg once daily (or 2.5 mg once daily in patients &gt;60 years of age); titrate daily as needed in 2.5 to 5 mg increments up to 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14685663','lexi-content-ref-Tietze.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14685663','lexi-content-ref-Tietze.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> Short-acting injection: 5 to 10 mg once; may repeat if needed after 2 to 4 hours; maximum total dose including oral: 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tietze.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tietze.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Non-ICU (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 1.25 to 5 mg once daily or as needed; titrate daily based on symptoms in 2.5 to 5 mg increments up to 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21911107','lexi-content-ref-Roy-Byrne.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21911107','lexi-content-ref-Roy-Byrne.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> Short-acting injection: Initial: 2.5 to 5 mg once daily or as needed. Maximum dose (including oral): 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21911107','lexi-content-ref-Roy-Byrne.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21911107','lexi-content-ref-Roy-Byrne.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7834615-81b5-448d-be0f-b6021963e20a">Delusional infestation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delusional infestation (delusional parasitosis) (off-label use):</b>
<b>Oral:</b> Initial: 2.5 mg once daily; increase dose based on response and tolerability at intervals ≥1 week up to 7.5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30543832','lexi-content-ref-Suh.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30543832','lexi-content-ref-Suh.2019'])">Ref</a></span>). Further increases up to 20 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18794644','lexi-content-ref-23789596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18794644','lexi-content-ref-23789596'])">Ref</a></span>). After achieving adequate response, maintain for ≥1 to 3 months before attempting to taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Suh.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Suh.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7100cdf-a3dd-4d7e-8069-adbb4a5c0ba7">Huntington disease–associated chorea, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Huntington disease–associated chorea, moderate to severe (alternative agent) (off-label use): </b>
<b>Oral:</b> Initial: 2.5 mg once daily; may increase dose based on response and tolerability in 2.5 to 5 mg increments at intervals ≥3 days up to 10 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12027832','lexi-content-ref-Suchowersky.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12027832','lexi-content-ref-Suchowersky.2019'])">Ref</a></span>). Further increases up to 30 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12410058','lexi-content-ref-12027832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12410058','lexi-content-ref-12027832'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Psychotic depression (adjunctive therapy with an antidepressant) (off-label use):</b>
<b>Oral:</b> Initial: 5 mg once daily; may increase dose based on response and tolerability in increments of 5 mg at intervals of 3 to 7 days up to 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19652123','lexi-content-ref-15232326','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19652123','lexi-content-ref-15232326','lexi-content-ref-23879318'])">Ref</a></span>). After 4 to 6 months of sustained recovery, some experts suggest discontinuing the antipsychotic and continuing antidepressant monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rothschild.2019','lexi-content-ref-12716238','lexi-content-ref-19880189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rothschild.2019','lexi-content-ref-12716238','lexi-content-ref-19880189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Treatment-resistant depression (adjunctive therapy with an antidepressant) (off-label, except labeled use as adjunctive to fluoxetine):</b>
<b>Oral:</b> Initial: 5 mg once daily; may gradually increase dose based on response and tolerability up to 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27486148','lexi-content-ref-Nelson.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27486148','lexi-content-ref-Nelson.2019'])">Ref</a></span>). A fixed-dose olanzapine/fluoxetine combination may be used instead of separate components. See “Dosing Conversion<i>”</i> below.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9b6efcc-04a3-4ed6-b324-fa912a4558fb">Nausea and vomiting associated with advanced cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting (persistent) associated with advanced cancer (off-label use): Oral: </b>5 mg once daily for 7 days; treatment may be continued beyond 7 days if clinically beneficial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32379269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32379269'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia (alternative agent) (PORT [Kreyenbuhl 2010])</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 mg once daily increasing to 10 mg once daily within several days <b>or</b> 10 mg once daily. Thereafter may increase dose based on response and tolerability in increments of 5 mg/day at intervals ≥1 week up to 20 mg/day; maximum dose: 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Further increases up to 30 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>). <b>Note:</b> Doses up to 50 mg/day have been evaluated in clinical studies; however, doses &gt;30 mg/day are associated with increased adverse effects and generally not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19589053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19589053'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> ER injection (olanzapine pamoate): <b>Note:</b> Establish tolerability using oral olanzapine prior to changing to ER injection. Overlap of oral olanzapine with initial dose of ER injection is not necessary. Due to the potential for a severe adverse reaction, patients must be observed for at least 3 hours after every injection. Maximum dose: 300 mg every 2 weeks or 405 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion of oral olanzapine to ER IM olanzapine:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Oral olanzapine 10 mg daily:</i> Initial dose: 210 mg every 2 weeks for 4 doses or 405 mg every 4 weeks for 2 doses; Maintenance dose: 150 mg every 2 weeks or 300 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Oral olanzapine 15 mg daily:</i> Initial dose: 300 mg every 2 weeks for 4 doses; Maintenance dose: 210 mg every 2 weeks or 405 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Oral olanzapine 20 mg daily:</i> Initial and maintenance dose: 300 mg every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment in elevated-risk patients:</i> Initial: A lower starting dose of 150 mg every 4 weeks is recommended in patients who are debilitated, at risk for orthostatic hypotension, may metabolize olanzapine more slowly (eg, nonsmoking, female, patients ≥65 years of age), or who may be more sensitive to adverse effects; increase dose with caution as clinically indicated.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversion:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Olanzapine/fluoxetine fixed-dose combination:</i> When using individual components of olanzapine with fluoxetine rather than the fixed-dose combination product, corresponding approximate dosage equivalents are as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 2.5 mg + fluoxetine 20 mg = combination strength 3/25</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 5 mg + fluoxetine 20 mg = combination strength 6/25</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 12.5 mg + fluoxetine 20 mg = combination strength 12/25</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 5 mg + fluoxetine 50 mg = combination strength 6/50</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 12.5 mg + fluoxetine 50 mg = combination strength 12/50</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral:</i> In the treatment of chronic psychiatric disease switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-16001094','lexi-content-ref-Post.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-16001094','lexi-content-ref-Post.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Long-acting injectable:</i> Switching to other treatments is generally advised if side effects are intolerable or treatment is not effective. However, if a patient insists on stopping treatment, gradual dose reduction to avoid withdrawal reactions is generally <b>not</b> needed with long-acting injectable antipsychotics. The risk of withdrawal symptoms from discontinuation of long-acting injectables is low because the rate of drug elimination is slow. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-28845181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-28845181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antipsychotics:</b> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991239"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection, Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10511917','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10511917','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10511917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10511917'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988483"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling except when used in combination with fluoxetine (as separate components) the initial olanzapine dose should be limited to 2.5 to 5 mg daily. Use with caution (cases of hepatitis and liver injury have been reported with olanzapine use). </p></div>
<div class="block doe drugH1Div" id="F203162"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose. Of note, use in certain indications may be appropriate (eg, adjunctive treatment of unipolar major depressive disorder, antiemetic, schizophrenia, bipolar disorder) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing. Dosages in the lower range of recommended adult dosing are generally sufficient for patient with late-onset-schizophrenia or psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10671383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10671383'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Short-acting IM, Oral: Consider lower starting dose of 2.5 to 5 mg daily for elderly patients; may increase as clinically indicated and tolerated with close monitoring of orthostatic blood pressure.</p>
<p style="text-indent:-2em;margin-left:2em;">ER IM: Consider lower starting dose of 150 mg every 4 weeks for elderly patients; increase dose with caution as clinically indicated.</p></div>
<div class="block dop drugH1Div" id="F203180"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16033" href="/d/html/16033.html" rel="external">see "Olanzapine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41c35bee-41f5-4f90-a7aa-13199c584f94">Agitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation:</b> Limited data available: <b>Note:</b> Due to risk of sedation and respiratory depression, separate parenteral olanzapine and benzodiazepine doses by at least 1 hour (oral dosing may need longer separation of doses due to delayed onset and peak effect relative to parenteral) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral (preferred): </i>Recommended for psychiatric emergencies in patients with developmental delay or who have been diagnosed with autism for severe or refractory agitation and in patients with oppositional defiant or conduct disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: Tablet, orally-disintegrating tablet: 2.5 to 10 mg. Dosing based on expert recommendations and very limited retrospective data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565','lexi-content-ref-28697164','lexi-content-ref-18216715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565','lexi-content-ref-28697164','lexi-content-ref-18216715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parenteral: </i>Recommended for psychiatric emergencies in patients with developmental delay or who have been diagnosed with autism for severe or refractory agitation (although ideally want to avoid IM in these patients) and in patients with oppositional defiant or conduct disorder, mania, or psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;10 years: IM (short acting): 1.25 mg to 5 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28697164','lexi-content-ref-17201611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28697164','lexi-content-ref-17201611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents: IM (short acting): 5 to 10 mg; dose may be repeated &gt;2 hours post initial injection based on pharmacokinetic data and experience in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28697164','lexi-content-ref-17201611','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28697164','lexi-content-ref-17201611','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing based on retrospective reports of IM olanzapine use in an emergency department (n=124; age range: 10 to 18 years) which showed efficacy in 77% of patients (ie, no further sedation required) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28697164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28697164'])">Ref</a></span>); and in an inpatient psychiatric setting to treat acute agitation associated with bipolar disorder or schizophrenia which included 50 pediatric patients (children [n=15; mean age: 11 years]; adolescents [n=35; mean age: 15 years]) and evaluated 163 doses administered; results showed a 90.2% response rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17201611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17201611'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2be5d1b7-1f22-43b5-ba05-d622b2fdec4a">Anorexia nervosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anorexia nervosa</b>
<b>:</b> Limited data available; efficacy results variable; in trials, poor tolerability reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25901778','lexi-content-ref-32021688','lexi-content-ref-21663423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25901778','lexi-content-ref-32021688','lexi-content-ref-21663423'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Olanzapine role in management of anorexia nervosa not defined; some suggest a short-term trial in patients with severe anxiety, obsessive thinking, extreme agitation, or hyperactivity, and resistance to refeeding or weight phobia as adjunct therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25901778','lexi-content-ref-32021688','lexi-content-ref-30700054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25901778','lexi-content-ref-32021688','lexi-content-ref-30700054'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 years and Adolescents: Oral: Initial: 0.625 to 1.25 mg once daily; may titrate; reported range: 1.25 to 12.5 mg/day; however, it has been suggested that higher doses (&gt;2.5 mg once daily) may not be associated with greater efficacy. In small trials and several case reports, 1.25 to 2.5 mg once daily was shown to improve BMI and other disease-related symptoms (eg, eating attitudes, anxiety, sleep); another case series used initial doses of 2.5 mg once daily and final doses of 5 to 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12474205','lexi-content-ref-32021688','lexi-content-ref-17190846','lexi-content-ref-20415608','lexi-content-ref-11469288','lexi-content-ref-18000964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12474205','lexi-content-ref-32021688','lexi-content-ref-17190846','lexi-content-ref-20415608','lexi-content-ref-11469288','lexi-content-ref-18000964'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d0a6293e-9107-4637-9f4a-4141688c2915">Bipolar I disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar I disorder (acute mania or episodes with mixed features): Note:</b> Olanzapine is not considered first-line therapy due to increased incidence of adverse effects identified in adolescent trials including weight gain and other metabolic abnormalities; neurological side effects may also occur; consider risks versus benefits prior to therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616','lexi-content-ref-30312108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616','lexi-content-ref-30312108'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;6 years: Limited data available: Oral: Initial: 1.25 mg once daily; increase at weekly intervals according to response and tolerability to target dose: 10 mg/day. Dosing based on an open-label trial in 15 children (mean age: 5 ± 0.8 years; mean weight: 20.8 kg; mean required dose: 6.3 ± 2.3 mg/day) that showed significant improvement in manic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16239162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16239162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: Limited data available: Oral: Initial: 2.5 mg once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11642474','lexi-content-ref-15725966','lexi-content-ref-19877978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11642474','lexi-content-ref-15725966','lexi-content-ref-19877978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: Initial: 2.5 to 5 mg once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day. In adolescent flexible-dosing (2.5 to 20 mg/day) clinical trials, the mean modal dose was 10.7 mg/day (mean dose: 8.9 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15725966','lexi-content-ref-17898346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15725966','lexi-content-ref-17898346'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="551907b3-cac7-4b7c-9167-6c86f50250d3">Chemotherapy-induced nausea and vomiting; breakthrough, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting (CINV); breakthrough, refractory:</b> Limited data available: <b>Note:</b> For highly emetogenic chemotherapy, evidenced-based clinical practice guidelines suggest the addition of olanzapine to existing CINV regimen for treatment of breakthrough CINV and for prevention of CINV in patients who have refractory CINV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26960036']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26960036'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Oral: Tablet, orally-disintegrating tablet: 0.1 to 0.14 mg/kg/dose once or twice daily; round dose to nearest 1.25 mg; in trials, olanzapine was combined with standard CINV regimens that included aprepitant, dexamethasone, and ondansetron or granisetron (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26960036','lexi-content-ref-25328089','lexi-content-ref-32931400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26960036','lexi-content-ref-25328089','lexi-content-ref-32931400'])">Ref</a></span>). Dosing based on a prospective, open-label, parallel group trial in 231 pediatric patients ≥5 years of age (n=115 olanzapine treatment group; median age: 12.5 years; median weight: 34 kg). In the olanzapine treatment group, patients received olanzapine throughout the chemotherapy block and for 3 days at the conclusion; results showed a significantly higher proportion of patients had a complete response (no nausea and no rescue medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32931400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32931400'])">Ref</a></span>). A retrospective evaluation of 60 pediatric patients (128 chemotherapy blocks; median age: 13.2 years; range: 3 to ~18 years) with poorly controlled CINV received olanzapine and reported complete vomiting control in the acute phase in 65% of the evaluated chemotherapy blocks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25328089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25328089'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4046ce5d-9307-407c-94cd-60eb5889392b">Delirium, ICU setting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delirium, ICU setting: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥7 months to Children &lt;3 years: Very limited data available: Oral: Orally disintegrating tablets: Reported range: 0.625 to 1.25 mg once daily (at bedtime) or twice daily; based on experience in older pediatric patients, therapy should be initiated at low dose and then titrated as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21336229','lexi-content-ref-23782129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21336229','lexi-content-ref-23782129'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Limited data available: Oral: Tablets, orally disintegrating tablets: Usual initial range: 1.25 to 5 mg once daily (at bedtime) or twice daily; doses on the higher end of the range should be reserved for larger or extremely agitated patients; therapy should be initiated at low dose and then titrated as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31214423','lexi-content-ref-22364403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31214423','lexi-content-ref-22364403'])">Ref</a></span>). In trials, once symptoms were controlled, doses were decreased over time; average reported duration of therapy was 26.5 days (range: 1 to 132 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31214423','lexi-content-ref-22364403','lexi-content-ref-24898718','lexi-content-ref-23782129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31214423','lexi-content-ref-22364403','lexi-content-ref-24898718','lexi-content-ref-23782129'])">Ref</a></span>). In the largest reported experience (n=78, age range: 1 to 18 years), a retrospective, descriptive trial reported a mean initial <b>total</b> daily dose of 4 mg/day and a mean maximum <b>total</b> daily dose of 10 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22364403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22364403'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia: Note:</b> Olanzapine may not be considered first-line therapy by clinicians due to increased incidence of adverse effects identified in adolescent trials including weight gain and other metabolic abnormalities; neurological side effects may also occur; consider risks versus benefits prior to therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23972700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23972700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years (limited data available in ages &lt;13 years) and Adolescents: Oral: Initial: 2.5 to 5 mg once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day. <b>Note:</b> Doses up to 30 mg/day were used in one study of adolescents who were treatment refractory; however, some patients did not tolerate doses &gt;20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17651705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17651705'])">Ref</a></span>); safety and efficacy of doses &gt;20 mg/day have not been fully evaluated. In adolescent flexible-dosing (2.5 to 20 mg/day) clinical trials, the mean modal dose was 12.5 mg/day (mean dose: 11.1 mg/day). Dosing in children is based on 2 double-blind comparison studies which included both children and adolescents (n=35, age: 8 to 19 years with seven children; n=13, age: 7 to 16 years [mean age: 12.8 + 2.4 years]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16818861','lexi-content-ref-18794207']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16818861','lexi-content-ref-18794207'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="308cbb9f-ebfb-4bbc-90ee-cd1c4f6c900c">Tourette syndrome, tic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, tic disorder:</b> Limited data available: <b>Note: </b>Not considered a therapeutic option in expert guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31061208','lexi-content-ref-31570648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31061208','lexi-content-ref-31570648'])">Ref</a></span>) due to increased incidence of adverse effects identified in pediatric patients including weight gain and other metabolic abnormalities and neurological side effects; consider risks versus benefits prior to therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22397999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22397999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≤40 kg: Oral: Initial: 2.5 mg every other day for 3 days, increase to 2.5 mg every day for remainder of week; increase to 5 mg/day by second week if needed; then increase in 5 mg increments at weekly intervals as tolerated; maximum dose: 20 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &gt;40 kg: Oral: Initial: 2.5 mg every day for 3 days; increase to 5 mg every day for remainder of week if needed, then increase in 5 mg increments at weekly intervals as tolerated; maximum dose: 20 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">An open-label study of 10 pediatric patients (7 to 13 years of age) reported significant reductions in tic severity (Yale Global Tic Severity Scale [YGTSS]) from baseline at a mean final dose of 14.5 mg/day after 8 weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15319022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15319022'])">Ref</a></span>). An open-label trial of 12 children and adolescents (7 to 14 years of age) reported a significant reduction (30%) in total tic severity (YGTSS) at a final mean dose of 11.3 mg/day (range: 2.5 to 20 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18928414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18928414'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51131691"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents: No dosage adjustment required. Not removed by dialysis.</p></div>
<div class="block dohp drugH1Div" id="F51131692"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents: Use with caution. Dosage adjustment may be necessary; however, no specific recommendations exist. Monitor closely.</p></div>
<div class="block arsc drugH1Div" id="F54959837"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic activity at usual therapeutic doses is generally considered to be moderate, relative to other second-generation antipsychotics (other than clozapine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10831017','lexi-content-ref-16928430','lexi-content-ref-20187598','lexi-content-ref-15641877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10831017','lexi-content-ref-16928430','lexi-content-ref-20187598','lexi-content-ref-15641877'])">Ref</a></span>). However, dose-dependent increases in anticholinergic activity have been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16928430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16928430'])">Ref</a></span>). Anticholinergic effects include <b>constipation</b>, <b>urinary retention</b>, and <b>xerostomia. </b>In older adults, some scales have classified olanzapine as having a high anticholinergic burden which may lead to new-onset<b> delirium</b>, <b>cognitive dysfunction</b>, and<b> falling. </b>However, there is no standardized tool for measuring anticholinergic burden in older adults and varying scales have also ranked olanzapine as low or moderate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23642462','lexi-content-ref-29983780','lexi-content-ref-11748787','lexi-content-ref-17224707','lexi-content-ref-30484239','lexi-content-ref-25879993','lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23642462','lexi-content-ref-29983780','lexi-content-ref-11748787','lexi-content-ref-17224707','lexi-content-ref-30484239','lexi-content-ref-25879993','lexi-content-ref-31342625'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; believed to be mediated primarily through antagonism at muscarinic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10831017','lexi-content-ref-11465633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10831017','lexi-content-ref-11465633'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Variable and dependent upon:</p>
<p style="text-indent:-2em;margin-left:8em;">• Total cumulative anticholinergic burden (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline cognitive function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Interindividual variability of the pharmacokinetic and pharmacodynamic parameters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dyslipidemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Olanzapine is strongly associated with dyslipidemia in adult and adolescent patients, which is a component of the metabolic syndrome observed with this pharmacologic class. Dyslipidemia observed with olanzapine primarily manifests as <b>hypercholesterolemia</b> and/or <b>hypertriglyceridemia</b>, including cases of severe hypertriglyceridemia (&gt;600 mg/dL) and acute <b>pancreatitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27807566','lexi-content-ref-21495734','lexi-content-ref-17346932','lexi-content-ref-11054978','lexi-content-ref-21487466','lexi-content-ref-23261075','lexi-content-ref-17017841','lexi-content-ref-17012695','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27807566','lexi-content-ref-21495734','lexi-content-ref-17346932','lexi-content-ref-11054978','lexi-content-ref-21487466','lexi-content-ref-23261075','lexi-content-ref-17017841','lexi-content-ref-17012695','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; metabolic alterations from antipsychotics can develop in as short as 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747245','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747245','lexi-content-ref-26218604'])">Ref</a></span>). One case series observed olanzapine-induced hypertriglyceridemia occurred with a time to peak as early as 2 months following initiation in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11476120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11476120'])">Ref</a></span>). Increases in fasting total cholesterol, LDL cholesterol, and triglycerides were generally greater in adolescent patients when compared to adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of hyperlipidemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26946767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26946767'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• BMI &gt;25 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26946767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26946767'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21127693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21127693'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population primarily due to cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotics: Risk of dyslipidemia and overall metabolic disturbances appears to be high with olanzapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Olanzapine may cause extrapyramidal symptoms (EPS), also known as drug-induced movement disorders. Antipsychotics can cause four main <b>extrapyramidal reactions</b>: Acute <b>dystonia</b>, drug-induced <b>parkinsonism</b>, <b>akathisia</b>, and <b>tardive dyskinesia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-12927004','lexi-content-ref-23428782','lexi-content-ref-20187598','lexi-content-ref-24313745','lexi-content-ref-21508932','lexi-content-ref-12447030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-12927004','lexi-content-ref-23428782','lexi-content-ref-20187598','lexi-content-ref-24313745','lexi-content-ref-21508932','lexi-content-ref-12447030'])">Ref</a></span>). EPS presenting as <b>dysphagia</b>, esophageal dysmotility, or aspiration have also been reported with antipsychotics, which may not be recognized as EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> EPS: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DSouza.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DSouza.2020'])">Ref</a></span>). Tardive dyskinesia: Time related (delayed); results from chronic exposure to dopamine 2 receptor antagonists leading to up-regulation of these receptors over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:0em;margin-left:4em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia:</span> Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism:</span> Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia:</span> Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases, and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia: </span>Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a dopamine 2 receptor antagonist and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization, and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with extrapyramidal symptoms)</span>: Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DSouza.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DSouza.2020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DSouza.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DSouza.2020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19861668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19861668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Olanzapine has a mild to moderate propensity to cause EPS; however, risk is dose-dependent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-20187598','lexi-content-ref-24313745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-20187598','lexi-content-ref-24313745'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DSouza.2020','lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DSouza.2020','lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DSouza.2020','lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DSouza.2020','lexi-content-ref-10473482'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tardive dyskinesia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Race (White or African descent). <b>Note</b>: Although early literature supported race as a potential risk factor for tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8102845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8102845'])">Ref</a></span>), newer studies have challenged this assertion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28146614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28146614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Esophageal dysfunction (associated with EPS):</p>
<p style="text-indent:-2em;margin-left:8em;">• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults &gt;75 years of age (may be risk factor due to age-related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukopenia</b>, <b>neutropenia</b>, and <b>thrombocytopenia</b> have rarely been reported with olanzapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15150680','lexi-content-ref-21058927','lexi-content-ref-30582126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15150680','lexi-content-ref-21058927','lexi-content-ref-30582126'])">Ref</a></span>). <b>Agranulocytosis </b>and <b>pancytopenia</b> have also been very rarely reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28387211','lexi-content-ref-11817522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28387211','lexi-content-ref-11817522'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; olanzapine has a chemical structure similar to clozapine (which also has hematologic side effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Alageel.2016','lexi-content-ref-15150680','lexi-content-ref-28387211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Alageel.2016','lexi-content-ref-15150680','lexi-content-ref-28387211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be insidious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced leukopenia/neutropenia or low white blood cell count/absolute neutrophil count</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30582126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30582126'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Olanzapine is strongly associated with <b>hyperglycemia</b> in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class. Glycemic abnormalities range from mild <b>insulin resistance</b> to <b>new-onset diabetes mellitus, hyperglycemic hyperosmolar coma</b>, and <b>diabetic ketoacidosis,</b> including fatal cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18801826','lexi-content-ref-15166774','lexi-content-ref-12804130','lexi-content-ref-20394794','lexi-content-ref-23278567','lexi-content-ref-27512491','lexi-content-ref-12126218','lexi-content-ref-20187598','lexi-content-ref-11261526','lexi-content-ref-26218604','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18801826','lexi-content-ref-15166774','lexi-content-ref-12804130','lexi-content-ref-20394794','lexi-content-ref-23278567','lexi-content-ref-27512491','lexi-content-ref-12126218','lexi-content-ref-20187598','lexi-content-ref-11261526','lexi-content-ref-26218604','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23278567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23278567'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; new-onset diabetes has been observed within the first 3 months to a median onset of 3.9 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28099349','lexi-content-ref-22854034','lexi-content-ref-18348593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28099349','lexi-content-ref-22854034','lexi-content-ref-18348593'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• African American race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12046641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12046641'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Exposures to other agents that also increase the risk of hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risk of metabolic disturbances appears to be high with olanzapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperprolactinemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In adults, olanzapine is typically associated with a lower risk of causing significant effects on prolactin compared to other second-generation antipsychotics with a higher risk (such as risperidone), although there are case reports of hyperprolactinemia in olanzapine-treated adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31417404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31417404'])">Ref</a></span>). However, in pediatric patients, the risk may be higher. A higher incidence of <b>increased serum prolactin </b>has been observed in adolescents receiving olanzapine compared to adults. Studies involving both children and adolescents (mostly short-term data) have also observed a statistically significant increase in serum prolactin levels during therapy compared to baseline levels. Hyperprolactinemia may lead to <b>gynecomastia, galactorrhea not associated with childbirth, amenorrhea, sexual disorder,</b> and infertility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29805808','lexi-content-ref-19113797','lexi-content-ref-27825323','lexi-content-ref-15456328','lexi-content-ref-22372514','lexi-content-ref-18759640','lexi-content-ref-19706318','lexi-content-ref-19702492','lexi-content-ref-20871665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29805808','lexi-content-ref-19113797','lexi-content-ref-27825323','lexi-content-ref-15456328','lexi-content-ref-22372514','lexi-content-ref-18759640','lexi-content-ref-19706318','lexi-content-ref-19702492','lexi-content-ref-20871665'])">Ref</a></span>). Although long-term effects of elevated prolactin levels have not been fully evaluated, some studies have also suggested a possible association between hyperprolactinemia and an increased risk for breast and/or pituitary tumors and osteopenia/osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23983962','lexi-content-ref-19113797','lexi-content-ref-20331935','lexi-content-ref-10718830','lexi-content-ref-16633146','lexi-content-ref-19702492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23983962','lexi-content-ref-19113797','lexi-content-ref-20331935','lexi-content-ref-10718830','lexi-content-ref-16633146','lexi-content-ref-19702492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (although some data involving olanzapine are inconsistent); antagonism of dopamine D<sub>2</sub> receptors in the tuberoinfundibular dopaminergic pathway which causes disinhibition of prolactin release resulting in hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31417404','lexi-content-ref-19958039','lexi-content-ref-24677189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31417404','lexi-content-ref-19958039','lexi-content-ref-24677189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset of antipsychotic-induced hyperprolactinemia is typically within a few weeks following initiation or dosage increase but may also arise after long-term stable use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>). Data involving children and adolescents receiving olanzapine showed significantly higher prolactin levels at months 3 and 6 compared to month 1, and a lower level at month 12 compared to month 1 (although that difference was not statistically significant) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19706318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19706318'])">Ref</a></span>). Although data are limited, a study involving patients 15 to 60 years suggests olanzapine does not significantly affect serum prolactin levels in the long term (eg, &gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23131886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23131886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797'])">Ref</a></span>) <b>Note:</b> Some data with olanzapine show inconsistent evidence for a dose relationship (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31417404','lexi-content-ref-24677189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31417404','lexi-content-ref-24677189'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (particularly those of reproductive age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-19113797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797','lexi-content-ref-19364288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797','lexi-content-ref-19364288'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine specifically:</p>
<p style="text-indent:-2em;margin-left:8em;">• Some D<sub>2</sub> receptor and 5-HT2<sub>A</sub> receptor gene polymorphisms (potential risk factor affecting prolactin levels with olanzapine therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24677189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24677189'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Delayed <b>hypersensitivity reactions</b> range from benign<b> skin photosensitivity</b>, <b>purpuric rash,</b> and <b>fixed drug eruptions</b> to more serious reactions, such as <b>vasculitis</b> and severe cutaneous adverse reactions (SCARs), including <b>acute generalized exanthematous pustulosis</b> and <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24765884','lexi-content-ref-28852258','lexi-content-ref-16696448','lexi-content-ref-16089244','lexi-content-ref-FDASafety.2016','lexi-content-ref-30581543','lexi-content-ref-22217947','lexi-content-ref-17460408','lexi-content-ref-16698917','lexi-content-ref-28784381','lexi-content-ref-22157728','lexi-content-ref-11217818','lexi-content-ref-29600715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24765884','lexi-content-ref-28852258','lexi-content-ref-16696448','lexi-content-ref-16089244','lexi-content-ref-FDASafety.2016','lexi-content-ref-30581543','lexi-content-ref-22217947','lexi-content-ref-17460408','lexi-content-ref-16698917','lexi-content-ref-28784381','lexi-content-ref-22157728','lexi-content-ref-11217818','lexi-content-ref-29600715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic. Delayed hypersensitivity reactions, including fixed drug eruptions and SCARs are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26339470'])">Ref</a></span>). Olanzapine can form <i>N</i>-oxide metabolites, which may contribute to the development of these reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29600715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29600715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed hypersensitivity reactions: Fixed drug eruptions: Intermediate; occur 7 to 10 days after initiation. Other reactions (including SCARs): Varied; usually occur between 7 to 14 days and up to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014','lexi-content-ref-17460408','lexi-content-ref-22157728','lexi-content-ref-11217818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014','lexi-content-ref-17460408','lexi-content-ref-22157728','lexi-content-ref-11217818'])">Ref</a></span>) but may also occur within 4 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16696448','lexi-content-ref-28784381']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16696448','lexi-content-ref-28784381'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Although potential cross-reactivity has been postulated between olanzapine and carbamazepine in a patient who developed DRESS to both agents, this may represent a reaction to 2 unrelated drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24765884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24765884'])">Ref</a></span>) or neosensitization to multiple drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28845181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28845181'])">Ref</a></span>). Despite the chemical similarity between clozapine, olanzapine, and quetiapine, no cross-reactions have been reported between these atypical antipsychotics to date.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older patients</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075'])">Ref</a></span>). In addition, an increased incidence of cerebrovascular effects (eg, <b>cerebrovascular accident</b>,<b> transient ischemic attacks</b>), including fatalities, have been reported in placebo-controlled olanzapine trials in elderly patients with dementia-related psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416','lexi-content-ref-24158020','lexi-content-ref-16166184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416','lexi-content-ref-24158020','lexi-content-ref-16166184'])">Ref</a></span>). Of note, olanzapine is not approved for the treatment of dementia-related psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-Kales.2012','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-Kales.2012','lexi-content-ref-25786075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome</b> (NMS), although the incidence is less with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with olanzapine, including monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-24253372','lexi-content-ref-27863115','lexi-content-ref-12766935','lexi-content-ref-14613516','lexi-content-ref-22854034','lexi-content-ref-18628446','lexi-content-ref-22626633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-24253372','lexi-content-ref-27863115','lexi-content-ref-12766935','lexi-content-ref-14613516','lexi-content-ref-22854034','lexi-content-ref-18628446','lexi-content-ref-22626633'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17414689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17414689'])">Ref</a></span>). However, there are many cases of NMS occurring months after stable therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12766935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12766935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males are twice as likely to develop NMS compared to females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9735957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9735957'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium or a benzodiazepine (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Disorganized speech or behavior (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Intramuscular administration of an antipsychotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dosage escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Olanzapine may cause <b>orthostatic hypotension </b>(although at a lower prevalence compared to first generation antipsychotics and certain atypicals, such as clozapine, risperidone, and quetiapine) and accompanying <b>tachycardia </b>and<b> dizziness </b>in adults, particularly with rapid titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25298577','lexi-content-ref-25912545','lexi-content-ref-11808820','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25298577','lexi-content-ref-25912545','lexi-content-ref-11808820','lexi-content-ref-20187598'])">Ref</a></span>). Orthostatic hypotension may result in a subsequent <b>falling</b> and fracture, particularly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25581312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25581312'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Orthostatic hypotension is attributed to alpha-1 adrenergic receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25912545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25912545'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; per the manufacturer’s labeling, orthostatic hypotension is most common during the initial dose titration but can also occur following subsequent dose increases.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Known cardiovascular diseases (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities) or cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Known predisposing conditions (eg, hypovolemia/dehydration)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications that also cause or exacerbate orthostatic hypotension (eg, tricyclic antidepressants, antihypertensive medications)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Post-injection delirium/sedation syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Olanzapine pamoate, the long-acting intramuscular injectable formulation, is associated with rare cases of <b>post-injection delirium/sedation syndrome</b> (PDSS), characterized by sedation (ranging from mild in severity to a coma-like state) and/or delirium (eg, agitation disorientation, confusion, irritability). Recovery is expected by 72 hours. Due to the risk of PDSS, a risk evaluation and mitigation strategy (REMS) program, called the Patient Care Program, is required with olanzapine pamoate use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20537128','lexi-content-ref-25424243','lexi-content-ref-20537130','lexi-content-ref-24226327','lexi-content-ref-30747749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20537128','lexi-content-ref-25424243','lexi-content-ref-20537130','lexi-content-ref-24226327','lexi-content-ref-30747749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Since patients with PDSS exhibit symptoms consistent with an oral overdose of olanzapine, the mechanism is believed to be due to accidental intravascular entry of a portion of the dose, likely following vessel injury during the injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28811926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28811926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; the vast majority of patients (80% to 90%) experience PDSS within the first hour of IM injection (median onset: 25 minutes postinjection), with most of the remainder of patients experiencing an onset between 1 hour and ≤3 hours; however, some patients have a time to onset at &gt;3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20537128','lexi-content-ref-28811926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20537128','lexi-content-ref-28811926'])">Ref</a></span>). PDSS may occur with any injection; one case report describes PDSS following a patient’s 31<sup>st</sup> scheduled injection (patient previously received 1.5 years of injections without PDSS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30747749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30747749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> No clear risk factors have been identified (Detke 2010), although the following have been suggested:</p>
<p style="text-indent:-2em;margin-left:8em;">• Although PDSS can occur even with proper injection technique, improper injection technique and/or improper aspiration (to verify blood is not visible prior to injection) may increase the risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25424243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25424243'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Decreased BMI (weak evidence) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20537128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20537128'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (weak evidence) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20537128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20537128'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (weak evidence) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20537128','lexi-content-ref-28811926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20537128','lexi-content-ref-28811926'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (weak evidence) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28811926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28811926'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Olanzapine has been associated with a mild degree of <b>prolonged QT interval on ECG</b>. In a study of 24 healthy psychiatric patients reaching steady state on olanzapine 20 mg/day, the mean change in QTc was 1.7 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11305706','lexi-content-ref-14709949','lexi-content-ref-25168784','lexi-content-ref-16096514','lexi-content-ref-22114630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11305706','lexi-content-ref-14709949','lexi-content-ref-25168784','lexi-content-ref-16096514','lexi-content-ref-22114630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Likely dose-related (but some evidence is inconsistent/conflicting); olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11305706','lexi-content-ref-17092964','lexi-content-ref-21823168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11305706','lexi-content-ref-17092964','lexi-content-ref-21823168'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/torsades de pointes (TdP) (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sedation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedated state</b>
<b>(drowsiness) </b>is common with use in all ages and may cause nonadherence, impair physical and mental abilities, and may result in subsequent <b>falli</b>
<b>ng </b>and fracture, particularly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28141623','lexi-content-ref-25581312','lexi-content-ref-24003306','lexi-content-ref-21127693','lexi-content-ref-24313745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28141623','lexi-content-ref-25581312','lexi-content-ref-24003306','lexi-content-ref-21127693','lexi-content-ref-24313745'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Sedation is believed to be due to H<sub>1 </sub>antagonism, leading to potential CNS depressant effects; olanzapine is considered a potent H<sub>1</sub> receptor blocker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16001094','lexi-content-ref-10340682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16001094','lexi-content-ref-10340682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (sedation appears to be more prevalent compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21127693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21127693'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (may increase risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24313745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24313745'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics have been associated with <b>sexual disorder</b> in both males and females. Antipsychotic treatment has been associated with effects on all phases of sexual activity (libido, arousal, and orgasm); however, many patients with schizophrenia experience more frequent sexual dysfunction, with or without antipsychotic treatment. <b>Decreased libido</b>,<b> erectile dysfunction, </b>and <b>abnormal orgasm </b>have been reported with olanzapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244','lexi-content-ref-20048451','lexi-content-ref-21191308','lexi-content-ref-19264412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244','lexi-content-ref-20048451','lexi-content-ref-21191308','lexi-content-ref-19264412'])">Ref</a></span>)<b>. </b>Conversely, there are also rare case reports of<b> increased libido </b>occurring with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20600465','lexi-content-ref-32425825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20600465','lexi-content-ref-32425825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Antipsychotic-induced sexual dysfunction has been attributed to many potential mechanisms, including dopamine receptor antagonism, dopamine D<sub>2 </sub>receptor antagonism in the infundibular dopaminergic pathway causing hyperprolactinemia, histamine receptor antagonism, cholinergic receptor antagonism, and alpha-adrenergic receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>). Of note, in adults, olanzapine is associated with a lower propensity for hyperprolactinemia compared to certain other antipsychotics with a high risk, such as risperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-23737244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperprolactinemia (although a correlation with sexual dysfunction has been observed, a relationship has not been confirmed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (the prevalence of antipsychotic-induced sexual dysfunction in patients with schizophrenia is high [~50% to 60% compared with 31% of men in the general population]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22533871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22533871'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Contrasting evidence; some studies have found a high prevalence of sexual dysfunction with olanzapine, while other studies have reported lower rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12623765','lexi-content-ref-23737244','lexi-content-ref-21191308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12623765','lexi-content-ref-23737244','lexi-content-ref-21191308'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics may impair the body’s ability to regulate core body temperature, which may cause a potentially life-threatening <b>heatstroke </b>during predisposing conditions such as a heat wave or strenuous exercise. There are also several case reports of potentially life-threatening <b>hypothermia </b>associated with olanzapine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17698676','lexi-content-ref-18615174','lexi-content-ref-24294486','lexi-content-ref-26503496','lexi-content-ref-11235936','lexi-content-ref-21592373','lexi-content-ref-30398998','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17698676','lexi-content-ref-18615174','lexi-content-ref-24294486','lexi-content-ref-26503496','lexi-content-ref-11235936','lexi-content-ref-21592373','lexi-content-ref-30398998','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D<sub>2 </sub>antagonism may cause an increase in body temperature, while 5-HT<sub>2a</sub> (serotonin) receptor antagonism may cause a decrease in body temperature. Of note, olanzapine has a stronger affinity for serotonin 5-HT<sub>2a</sub> receptors compared to D<sub>2 </sub>receptors. In addition, antagonism of peripheral alpha-adrenergic receptors has also been suggested as a factor in the hypothermic effect by inhibiting peripheral responses to cooling (vasoconstriction and shivering) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke:</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hypothermia:</p>
<p style="text-indent:-2em;margin-left:8em;">• In general, predisposing risk factors include advanced age, a cerebrovascular accident or preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis benzodiazepine use, alcohol intoxication, or kidney or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of antipsychotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Olanzapine is strongly associated with significant <b>weight gain </b>(increase of ≥7% from baseline) in children, adolescents, and adults, which is a component of the metabolic syndrome observed with this pharmacologic class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31524318','lexi-content-ref-19958039','lexi-content-ref-19861668','lexi-content-ref-25590213','lexi-content-ref-21127693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31524318','lexi-content-ref-19958039','lexi-content-ref-19861668','lexi-content-ref-25590213','lexi-content-ref-21127693'])">Ref</a></span>). Compared to adult patients, adolescent patients had both greater magnitude of weight gain and greater proportion of patients with clinically significant weight gain.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects on weight gain by the different antipsychotic agents explained by differing affinity at these receptors. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-31039482','lexi-content-ref-24424705','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-31039482','lexi-content-ref-24424705','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; antipsychotic-induced weight gain usually occurs rapidly in the period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of obesity; parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-15998156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-15998156'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Factors associated with rapid weight gain in the initial period include: Younger age, lower BMI, more robust response to antipsychotic and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-25145624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-25145624'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness, such as negative symptoms, sedentary lifestyles, and unhealthy diets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861176'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Olanzapine is considered to have a high propensity for causing weight gain in children, adolescents, and adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21495734','lexi-content-ref-19861668','lexi-content-ref-28883731','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21495734','lexi-content-ref-19861668','lexi-content-ref-28883731','lexi-content-ref-20187598'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F203123"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Orthostatic hypotension (adults: 3% to 21%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">248</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">118</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,030</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Increased LDL cholesterol (fasting, increase by ≥30 mg/dL or from baseline normal [&lt;100 mg/dL] or borderline [≥100 mg/dL and &lt;160 mg/dL] to high [≥160 mg/dL]: 7% to 48%); increased serum cholesterol (fasting, increase by ≥40 mg/dL or from baseline normal [&lt;200 mg/dL] or borderline [≥200 mg/dL to &lt;240 mg/dL] to high [≥240 mg/dL]: 3% to 58%), increased serum glucose (fasting, from baseline normal [&lt;100 mg/dL] or borderline [≥100 and &lt;126 mg/dL] to high [≥126 mg/dL]: ≤26%), increased serum prolactin (adolescents: 47%; adults: 30%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Prolactin table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-prolactin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-prolactin')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Serum Prolactin</span>, increased serum triglycerides (fasting, increase by ≥50 mg/dL or from baseline normal [&lt;150 mg/dL] or borderline [&lt;150 mg/dL to &lt;200 mg/dL) to high [≥200 mg/dL]: 9% to 71%), weight gain (adolescents: 29% to 31%, has been reported as high as 89%; adults: 5% to 6%, has been reported as high as 64%)<span class="lexi-table-link-container"> (<a aria-label="Weight Gain table link" class="lexi-table-link" data-table-id="lexi-content-weight-gain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-gain')">table 3</a>)</span><span class="table-link" style="display:none;">Weight Gain</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Prolactin" frame="border" id="lexi-content-increased-serum-prolactin" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: </b>
<b>Increased Serum Prolactin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">47%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar I disorder</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Gain" frame="border" id="lexi-content-weight-gain" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Weight Gain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">72</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">35</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">248</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">118</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Constipation (4% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 4</a>)</span><span class="table-link" style="display:none;">Constipation</span>, dyspepsia (adolescents: 3%; adults: 7% to 11%), increased appetite (adolescents: 17% to 29%; adults: 3% to 6%), xerostomia (dose dependent: adolescents: 4% to 7%; adults: 3% to 22%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia')">table 5</a>)</span><span class="table-link" style="display:none;">Xerostomia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia or Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">179</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">248</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">118</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia" frame="border" id="lexi-content-xerostomia" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Xerostomia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">72</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">35</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">69</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">64</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Decreased serum bilirubin (adolescents: 22%), increased serum alanine aminotransferase (≥3 x ULN: 5% to 12%), increased serum aspartate aminotransferase (adolescents: 28%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Akathisia (3% to 27%)<span class="lexi-table-link-container"> (<a aria-label="Akathisia table link" class="lexi-table-link" data-table-id="lexi-content-akathisia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-akathisia')">table 6</a>)</span><span class="table-link" style="display:none;">Akathisia</span>, dizziness (adolescents: 7% to 8%; adults: 11% to 18%<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 7</a>)</span><span class="table-link" style="display:none;">Dizziness</span>); drowsiness (dose dependent: 20% to 48%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 8</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, extrapyramidal reaction (dose dependent: adolescents: 10%; adults: 15% to 32%)<span class="lexi-table-link-container"> (<a aria-label="Extrapyramidal Reaction table link" class="lexi-table-link" data-table-id="lexi-content-extrapyramidal-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-extrapyramidal-reaction')">table 9</a>)</span><span class="table-link" style="display:none;">Extrapyramidal Reaction</span>; fatigue (dose dependent: 2% to 14%), headache (adolescents: 17%), insomnia (12%), parkinsonism (8% to 20%; includes akinesia, cogwheel rigidity, hypokinesia, and mask-like face)<span class="lexi-table-link-container"> (<a aria-label="Parkinsonism table link" class="lexi-table-link" data-table-id="lexi-content-parkinsonism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-parkinsonism')">table 10</a>)</span><span class="table-link" style="display:none;">Parkinsonism</span>, sedated state (adolescents: 39% to 48%)<span class="lexi-table-link-container"> (<a aria-label="Sedated State table link" class="lexi-table-link" data-table-id="lexi-content-sedated-state" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sedated-state')">table 11</a>)</span><span class="table-link" style="display:none;">Sedated State</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Akathisia" frame="border" id="lexi-content-akathisia" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Akathisia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia or Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">179</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">64</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">69</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">248</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">118</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">72</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">35</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">248</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">118</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">48%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">72</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">35</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">69</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">64</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Extrapyramidal Reaction" frame="border" id="lexi-content-extrapyramidal-reaction" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Extrapyramidal Reaction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia or Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">179</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">69</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">64</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Parkinsonism" frame="border" id="lexi-content-parkinsonism" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Parkinsonism</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">69</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">64</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 ± 2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sedated State" frame="border" id="lexi-content-sedated-state" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Sedated State</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">48%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar I Disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">72</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">35</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Asthenia (dose dependent: 8% to 20%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Accidental injury (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Chest pain (3%), hypertension (2%), peripheral edema (3%), tachycardia (3%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 12</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Ecchymoses (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Breast changes (male and female adolescents: ≤2%; including discharge, enlargement, galactorrhea not associated with childbirth, gynecomastia, lactation disorder), increased gamma-glutamyl transferase (adolescents: 10%; adults: 2%), increased uric acid (4%), menstrual disease (2%; including amenorrhea, delayed menstruation, hypomenorrhea, oligomenorrhea)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (adolescents: 6%), diarrhea (adolescents: 3%), vomiting (≤4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Sexual disorder (≤2%; literature suggests an incidence up to 35% [Bobes 2003]; dysfunction includes: Anorgasmia, delayed ejaculation, erectile dysfunction, decreased libido, loss of libido, and orgasm abnormal), urinary incontinence (adults and older adults: ≥2%), urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased liver enzymes (adolescents: ≤8%), increased serum alkaline phosphatase (≥1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Abnormal gait (6%), articulation impairment (2%), falling (older adults: ≥2%), hypertonia (3%), personality disorder (5% to 8%), restlessness (adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (adults: 5%; adolescents: 2%), back pain (5%), dyskinesia (1%), limb pain (5% to 6%), muscle rigidity (adolescents: 2%), tremor (dose dependent: 4% to 7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Amblyopia (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (6%), epistaxis (adolescents: 3%), nasopharyngitis (adolescents: 4%), pharyngitis (4%), respiratory tract infection (adolescents: 3%), rhinitis (7%), sinusitis (adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Cerebrovascular accident (Gareri 2014), facial edema, syncope, transient ischemic attacks (Layton 2005), vasodilation</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Alopecia, skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Heavy menstrual bleeding</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distension, intestinal obstruction, nausea</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Difficulty in micturition, impotence, mastalgia, urinary frequency, urinary retention, urinary urgency</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Hypoproteinemia, leukocytosis (eosinophilia), neutropenia (Lander 2011), pancytopenia (Pang 2017), thrombocytopenia (Carrillo 2004)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Hyperbilirubinemia, liver steatosis</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Tongue edema</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Ataxia, chills, coma, dysarthria, hangover effect, seizure (Uvais 2018), stupor, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Osteoporosis</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Accommodation disturbance, dry eye syndrome, mydriasis</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Injection:</b> Adverse events are reported for the extended-release suspension for injection (olanzapine pamoate [Zyprexa Relprevv]) unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Nervous system: Headache (13% to 18%), sedated state (8% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Sedated State Inj table link" class="lexi-table-link" data-table-id="lexi-content-sedated-state-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sedated-state-inj')">table 13</a>)</span><span class="table-link" style="display:none;">Sedated State Inj</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sedated State Inj" frame="border" id="lexi-content-sedated-state-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Sedated State</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">405 mg/4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">106</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Hypertension (2% to 3%), hypotension (short-acting: 2%), orthostatic hypotension (short-acting: 1%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension Inj table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension-inj')">table 14</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension Inj</span>, prolonged QT interval on ECG (≤2%)<span class="lexi-table-link-container"> (<a aria-label="Prolonged QT Interval on ECG Inj table link" class="lexi-table-link" data-table-id="lexi-content-prolonged-qt-interval-on-ecg-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-prolonged-qt-interval-on-ecg-inj')">table 15</a>)</span><span class="table-link" style="display:none;">Prolonged QT Interval on ECG Inj</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension Inj" frame="border" id="lexi-content-orthostatic-hypotension-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia or Bipolar I Mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Prolonged QT Interval on ECG Inj" frame="border" id="lexi-content-prolonged-qt-interval-on-ecg-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Prolonged QT Interval on ECG</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">405 mg/4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">106</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Acne vulgaris (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Weight gain (short-term 8-week trial: 5% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Weight Gain Inj table link" class="lexi-table-link" data-table-id="lexi-content-weight-gain-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-gain-inj')">table 16</a>)</span><span class="table-link" style="display:none;">Weight Gain Inj</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Gain Inj" frame="border" id="lexi-content-weight-gain-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Weight Gain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">106</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">405 mg/4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (3%), diarrhea (5% to 7%), flatulence (1% to 2%), increased appetite (1% to 6%), nausea (long-acting: 4% to 5%; short-acting: &lt;1%), vomiting (6%), xerostomia (2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia Inj table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia-inj')">table 17</a>)</span><span class="table-link" style="display:none;">Xerostomia Inj</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia Inj" frame="border" id="lexi-content-xerostomia-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Xerostomia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">106</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">405 mg/4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Vaginal discharge (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased liver enzymes (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Viral infection (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection site reaction (4%, including abscess at injection site), pain at injection site (both formulations: 1% to 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Abnormal dreams (2%), abnormality in thinking (3%), akathisia (short-acting: 2% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Akathisia Inj table link" class="lexi-table-link" data-table-id="lexi-content-akathisia-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-akathisia-inj')">table 18</a>)</span><span class="table-link" style="display:none;">Akathisia Inj</span>, auditory hallucination (3%), dizziness (both formulations: 1% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness Inj table link" class="lexi-table-link" data-table-id="lexi-content-dizziness-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness-inj')">table 19</a>)</span><span class="table-link" style="display:none;">Dizziness Inj</span>, drowsiness (short-acting: 6%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness Inj table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness-inj')">table 20</a>)</span><span class="table-link" style="display:none;">Drowsiness Inj</span>, dysarthria (1% to 2%), extrapyramidal reaction (short-acting: 2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Extrapyramidal Reaction Inj table link" class="lexi-table-link" data-table-id="lexi-content-extrapyramidal-reaction-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-extrapyramidal-reaction-inj')">table 21</a>)</span><span class="table-link" style="display:none;">Extrapyramidal Reaction Inj</span>, fatigue (3% to 4%), pain (2% to 3%), parkinsonism (short-acting: 2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Parkinsonism Inj table link" class="lexi-table-link" data-table-id="lexi-content-parkinsonism-inj" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-parkinsonism-inj')">table 22</a>)</span><span class="table-link" style="display:none;">Parkinsonism Inj</span>, restlessness (3%), sleep disorder (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Akathisia Inj" frame="border" id="lexi-content-akathisia-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Akathisia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness Inj" frame="border" id="lexi-content-dizziness-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">405 mg/4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">106</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia or Bipolar I Mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness Inj" frame="border" id="lexi-content-drowsiness-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia or Bipolar I Mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Extrapyramidal Reaction Inj" frame="border" id="lexi-content-extrapyramidal-reaction-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Extrapyramidal Reaction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Parkinsonism Inj" frame="border" id="lexi-content-parkinsonism-inj" rules="all">
<caption style="text-align:center;">
<b>Olanzapine: Adverse Reaction: Parkinsonism</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Short-acting IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (3%), asthenia (short-acting: 2%), back pain (5%), muscle spasm (1% to 3%), stiffness (4%), tremor (long-acting: 3%; short-acting: 1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Otalgia (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (9%), nasal congestion (7%), nasopharyngitis (3% to 6%), pharyngolaryngeal pain (3%), sneezing (2%), upper respiratory tract infection (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Syncope (short-acting)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Confusion, postinjection delirium/sedation syndrome (Meyers 2010), speech disturbance</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (short-acting)</p>
<p style="text-indent:-2em;margin-left:4em;">Postmarketing (all formulations):</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Atrial fibrillation (Chou 2017), atrial flutter (Chou 2017), pulmonary embolism, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Eruptive xanthoma (Chang 2003), fixed drug eruption (rare: &lt;1%) (Chawla 2017), pruritus, purpuric rash (rare: &lt;1%) (Lin 2018), skin photosensitivity (benign, rare: &lt;1%) (Reddy 2019), skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Diabetes mellitus (new-onset) (Koller 2002), diabetic ketoacidosis (rare: &lt;1%) (Avella 2004), hypercholesterolemia (common: &gt;10%) (Olfson 2006), hyperglycemia (Bloch 2003; Solmi 2017), hyperglycemic hyperosmolar coma (rare: &lt;1%) (Ahuja 2008), hypertriglyceridemia (Kimmel 2013), increased libido (Stefanou 2020), insulin resistance (Chiu 2010)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Dysphagia (rare: &lt;1%) (Crouse 2018), necrotizing pancreatitis (rare: &lt;1%), pancreatitis (rare: &lt;1%) (Buszek 2016; Doucette 2000; Kerr 2007), sialorrhea</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Priapism (Farag 2019)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Agranulocytosis (rare: &lt;1%) (Tolosa-Vilella 2002), leukopenia (rare: &lt;1%) (Lander 2011)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Hepatic injury (cholestatic or mixed), hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Angioedema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:6em;">Immunologic: Acute generalized exanthematous pustulosis (rare: &lt;1%) (Christen 2006), drug reaction with eosinophilia and systemic symptoms (rare: &lt;1%) (Raz 2001), vasculitis (rare: &lt;1%) (Duggal 2005)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Cognitive dysfunction (Morrens 2007), delirium (less frequent: ≥1% to &lt;4%) (Pasina 2019), dystonia (less frequent: ≥1% to &lt;4%) (Hill 2014), heatstroke (rare: &lt;1%) (Jafferany 2008), hypothermia (rare: &lt;1%) (Parris 2011), neuroleptic malignant syndrome (rare: &lt;1%) (Kogoj 2003), restless leg syndrome, sleep apnea (obstructive) (Health Canada 2016; Shirani 2011), tardive dyskinesia (rare: &lt;1%) (Hill 2014), withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Oculogyric crises (tardive) (Bavle 2013)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Respiratory depression (Cole 2007)</p></div>
<div class="block coi drugH1Div" id="F203138"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to olanzapine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F203120"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperprolactinemia: May cause dose-related increases in prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown. Clinical manifestations of increased prolactin levels included menstrual-, sexual- and breast-related events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction, ischemic heart disease, or hypercholesterolemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI motility: Use with caution in patients with decreased GI motility (eg, paralytic ileus) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic disease or impairment; dose adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotic may aggravate motor disturbances (APA [Reus 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications that may lower seizure threshold. Elderly patients may be at increased risk of seizures because of an increased prevalence of predisposing factors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention (eg, benign prostatic hyperplasia): Use with caution in patients with urinary retention as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tobacco smokers: Olanzapine levels may be lower in patients who smoke. Smokers may require an increased daily dose (Tsuda 2014). Discontinuation of smoking should also merit a dose reduction as olanzapine levels may be higher be smoking cessations occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form-specific concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• IM formulations: There are two Zyprexa formulations for IM injection: Zyprexa Relprevv is an ER formulation and Zyprexa IntraMuscular is short-acting.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ER IM injection (Zyprexa Relprevv):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Postinjection delirium/sedation syndrome: Upon determining alert status, patient should be escorted to their destination and not drive or operate heavy machinery for the remainder of the day.</p>
<p style="text-indent:-2em;margin-left:8em;">Unexplained deaths: Two unexplained deaths in patients who received <i>Zyprexa Relprevv</i> have been reported. The patients died 3 to 4 days after receiving an appropriate dose of the drug. Both patients were found to have high blood concentrations of olanzapine postmortem. It is unclear if these deaths were the result of postinjection delirium sedation syndrome (PDSS) (FDA Safety Communication 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Short-acting IM injection (Zyprexa IntraMuscular):</i> Patients should remain recumbent if drowsy/dizzy until hypotension, bradycardia, and/or hypoventilation have been ruled out. Closely monitor for orthostasis prior to any repeat dosing. Concurrent use of IM/IV benzodiazepines is not recommended (fatalities have been reported, though causality not determined).</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Other warnings/precautions</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: IV administration has only been studied in emergency department settings, where patients can be closely monitored for respiratory depression (ie, pulse oximetry) (Chan 2013; Cole 2017; Martel 2016; Taylor 2017).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878568"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients. Medication therapy for pediatric patients with bipolar disorder and schizophrenia is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions.</p></div>
<div class="block foc drugH1Div" id="F26715079"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA: 10 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA Relprevv: 210 mg (1 ea); 300 mg (1 ea); 405 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA: 2.5 mg, 5 mg, 7.5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA: 15 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA Zydis: 5 mg, 10 mg, 15 mg, 20 mg [contains aspartame, methylparaben sodium, propylparaben sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 15 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F26730983"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F203140"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (OLANZapine Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $41.50 - $47.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (ZyPREXA Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $60.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (ZyPREXA Relprevv Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">210 mg (per each): $707.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1,010.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">405 mg (per each): $1,364.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (OLANZapine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.08 - $14.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $3.05 - $20.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $4.50 - $30.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $5.94 - $40.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (ZyPREXA Zydis Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $20.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $29.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $43.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $58.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (OLANZapine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $10.42 - $11.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $12.29 - $13.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $14.95 - $16.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $18.53 - $19.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $27.77 - $29.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $37.05 - $39.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (ZyPREXA Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $16.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $18.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $22.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $28.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $42.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $56.95</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867742"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA: 10 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA: 2.5 mg, 5 mg, 7.5 mg, 10 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA: 15 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyPREXA Zydis: 5 mg, 10 mg, 15 mg, 20 mg [contains aspartame, methylparaben sodium, propylparaben sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 15 mg, 20 mg</p></div>
<div class="block adm drugH1Div" id="F203135"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Short-acting injection: May be administered IM or IV (off-label route); do not administer injection subcutaneously. For IM administration, inject slowly, deep into muscle. For off-label IV route, administer by rapid IV push (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27745766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27745766'])">Ref</a></span>). If dizziness and/or drowsiness are noted, patient should remain recumbent until examination indicates postural hypotension and/or bradycardia are not a problem.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release injection: <b>For IM gluteal injection only</b>; do not administer IV or subcutaneously. After needle insertion into muscle, aspirate to verify that no blood appears. Do not massage injection site. Use diluent, syringes, and needles provided in convenience kit; obtain a new kit if aspiration of blood occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally-disintegrating: Remove from foil blister by peeling back (do not push tablet through the foil); place tablet in mouth immediately upon removal; tablet dissolves rapidly in saliva and may be swallowed with or without liquid. May be administered with or without food/meals.</p></div>
<div class="block admp drugH1Div" id="F52613458"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Remove from foil blister by peeling back foil (do not push tablet through the foil); place tablet in mouth immediately upon removal; tablet dissolves rapidly in saliva and may be swallowed with or without liquid. May be administered with or without food/meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IM (short-acting): For IM administration only; do not administer IV or subcutaneously; inject slowly, deep into muscle mass. If dizziness and/or drowsiness are noted, patient should remain recumbent until examination indicates postural hypotension and/or bradycardia are not a problem.</p></div>
<div class="block meg drugH1Div" id="F7874938"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Zyprexa and Zyprexa Zydis: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F020592s075%2C021086s049%2C021253s062lbl.pdf%23page%3D37&amp;token=brU%2BgMaeUXKePYieaqKnmUCE6gVdIXkStOS0%2B%2FkfcqVs8Ou62A%2BoM25NMLLtT%2F%2FGR9EKVO%2F5IpB7IkHKxJv%2F92Igp4YaPEITK53HG59CoKo5qvXX5XZ0OKg6SgztsIY0oz4OhrwHMYK9NlJQIpqFtg%3D%3D&amp;TOPIC_ID=9716" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s075,021086s049,021253s062lbl.pdf#page=37</a></p>
<p style="text-indent:-2em;margin-left:4em;">Zyprexa Relprevv: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F022173s036lbl.pdf%23page%3D29&amp;token=kjQsv5LB37rL%2BOtjjlE%2Ff1r8YckdMZevYb1sv1UmgwQUuQF9xQLUtk%2B3Ci6WbaTsIvKrzFs%2F1iSdDYD22ZksdPfrGlZsAA4qfevsf04%2B7vfDIbNhqH9c2pIPhQfPDH95&amp;TOPIC_ID=9716" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022173s036lbl.pdf#page=29</a></p></div>
<div class="block use drugH1Div" id="F203134"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression (acute) associated with psychiatric disorders (short-acting IM): </b>Treatment of acute agitation associated with schizophrenia and bipolar I mania.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder (oral): </b>Treatment of acute mania, acute episodes with mixed features of bipolar I disorder (as monotherapy or in combination with lithium or valproate), and maintenance treatment; treatment of bipolar depression in combination with fluoxetine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar), treatment resistant (oral): </b>Treatment of treatment-resistant depression in combination with fluoxetine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia (oral, ER IM): </b>Treatment of the manifestations of schizophrenia.</p></div>
<div class="block off-label drugH1Div" id="F25730993"><span class="drugH1">Use: Off-Label: Adult</span><p>Agitation/Aggression and psychosis associated with dementia; Anorexia nervosa; Bipolar disorder, hypomania; Chemotherapy-induced acute and delayed nausea or vomiting (high emetic risk [&gt;90%]), prevention; Chemotherapy-induced breakthrough nausea or vomiting, treatment; Delirium, hyperactive (ICU treatment); Delirium, hyperactive (non-ICU treatment); Delusional infestation (delusional parasitosis); Huntington disease-associated chorea; Major depressive disorder (unipolar) with psychotic features; Nausea and vomiting associated with advanced cancer</p></div>
<div class="block mst drugH1Div" id="F203206"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">OLANZapine may be confused with olsalazine, QUEtiapine</p>
<p style="text-indent:-2em;margin-left:4em;">ZyPREXA may be confused with CeleXA, Reprexain, Zestril, ZyrTEC</p>
<p style="text-indent:-2em;margin-left:4em;">ZyPREXA Zydis may be confused with Zelapar, zolpidem, zapelon</p>
<p style="text-indent:-2em;margin-left:4em;">ZyPREXA Relprevv may be confused with ZyPREXA IntraMuscular</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Olanzapine, when used long term (&gt;24 weeks) in pediatric patients &lt;18 years of age, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of metabolic syndrome (weight gain, hyperlipidemia, hyperglycemia) (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F203191"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2D6 (minor), UGT1A4; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F203125"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines: May enhance the adverse/toxic effect of OLANZapine. Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Clarithromycin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of ClomiPRAMINE. QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of ClomiPRAMINE. This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Weak): May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of DroPERidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of OLANZapine. Fexinidazole may increase the serum concentration of OLANZapine. Management: Monitor for increased olanzapine toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Flupentixol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of Imipramine. This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Propofol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of OLANZapine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of OLANZapine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): OLANZapine may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Saquinavir.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May diminish the therapeutic effect of OLANZapine. Tobacco (Smoked) may decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53589522"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Olanzapine may cause hyperprolactinemia, which may decrease reproductive function in both males and females.</p>
<p style="text-indent:0em;margin-top:2em;">Olanzapine may be used if treatment with an atypical antipsychotic is needed in a woman planning a pregnancy (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F2839122"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Olanzapine crosses the placenta and can be detected in cord blood at birth (Newport 2007; Schoretsanitis 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, an increased risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes has not been observed following maternal use of olanzapine (Brunner 2013; Damkier 2018; Huybrechts 2016). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetic properties of olanzapine are not significantly altered by pregnancy (Westin 2018); however, serum levels may change, even at a stable dose, possibly due to decreased CYP1A2 activity during the second and third trimesters (Stiegler 2014; Westin 2018). The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy are limited, as such, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is initiated during pregnancy, olanzapine may be used (Larsen 2015). The potential for excessive maternal weight gain and the development of gestational diabetes associated with olanzapine therapy should be considered (Damkier 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to olanzapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or https://www.womensmentalhealth.org/pregnancyregistry).</p></div>
<div class="block brc drugH1Div" id="F2839124"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Olanzapine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Olanzapine can be detected in breast milk following maternal use of oral or injectable preparations and the concentrations in breast milk are variable (Schoretsanitis 2019). Relative infant doses (RID) of 0.3% to 4% have been reported in the literature (Pacchiarotti 2016). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). Some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Using data from 6 women, the mean maximum breast milk concentration appeared 5.2 hours after the maternal dose (Gardiner 2003). Olanzapine has been detected in the serum of a breastfeeding infant; concentrations were highest when first measured at 4 months of age and decreased over the next 5 months, possibly due to CYP1A2 metabolism, which matures as the child ages. Maternal doses varied based on maternal symptoms, but ranged from 5 to 15 mg/day (Whitworth 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">In the majority of cases, adverse events have not been noted in breastfeeding infants (Pacchiarotti 2016). When observed, excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors and abnormal muscle movements) have been reported in infants exposed to olanzapine through breast milk. In general, infants exposed to second generation antipsychotics via breast milk should be monitored weekly for the first month of exposure for symptoms such as appetite changes, insomnia, irritability, or lethargy (Uguz 2016). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. When an antipsychotic medication is needed in a breastfeeding woman, olanzapine is preferred (Larsen 2015; Pacchiarotti 2016; Uguz 2016).</p></div>
<div class="block dic drugH1Div" id="F203141"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Tablets may be taken without regard to meals. Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F203129"><span class="drugH1">Monitoring Parameters</span>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Frequency of Antipsychotic Monitoring<sup>a,b</sup></b></p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">Monitoring parameter</p></th>
<th align="center">
<p style="text-indent:0em;">Frequency of monitoring</p></th>
<th align="center">
<p style="text-indent:0em;">Comments</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>For all monitoring parameters, it is appropriate to check at baseline and when clinically relevant (based on symptoms or suspected adverse reactions) in addition to the timeline.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> ADA 2004b; APA [Keepers 2020]; De Hert 2011; Gugger 2011; manufacturer's labeling.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Risk factors for extrapyramidal symptoms (EPS) include prior history of EPS, high doses of antipsychotics, young age (children and adolescents at higher risk than adults), and dopaminergic affinity of individual antipsychotic.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Risk factors for tardive dyskinesia include &gt;55 years of age; females; White or African ethnicity; presence of a mood disorder, intellectual disability, CNS injury, or past or current EPS.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adherence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Blood chemistries (electrolytes, renal function, liver function, TSH)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Annually</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">CBC</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">As clinically indicated</p></td>
<td align="center">
<p style="text-indent:0em;">Check frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extrapyramidal symptoms</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit; 4 weeks after initiation and dose change; annually. Use a formalized rating scale at least annually or every 6 months if high risk.<sup>c</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fall risk</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fasting plasma glucose/HbA<sub>1c</sub></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">12 weeks after initiation and dose change; annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Check more frequently than annually if abnormal. Follow diabetes guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lipid panel</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">12 weeks after initiation and dose change; annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Check more frequently than annually if abnormal. Follow lipid guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mental status and alertness</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Metabolic syndrome history</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Evaluate for personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prolactin</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Ask about symptoms at every visit until dose is stable. Check prolactin level if symptoms are reported.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hyperprolactinemia symptoms: changes in menstruation, libido, gynecomastia, development of galactorrhea, and erectile and ejaculatory function.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tardive dyskinesia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit; annually. Use a formalized rating scale at least annually or every 6 months if high risk.<sup>d</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Vital signs (BP, orthostatics, temperature, pulse, signs of infection)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit (at least weekly during first 3 to 4 weeks of treatment); 4 weeks after dose change.</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Weight/Height/BMI</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">8 and 12 weeks after initiation and dose change; quarterly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Consider monitoring waist circumference at baseline and annually, especially in patients with or at risk for metabolic syndrome.</p>
<p style="text-indent:0em;text-align:left;">Consider changing antipsychotic if BMI increases by ≥1 unit.</p>
<p style="text-indent:0em;text-align:left;">Some experts recommend checking weight and height at every visit.</p></td></tr></tbody></table>
<p style="text-indent:0em;margin-top:2em;">
<i>Additional monitoring parameters with administration of injection formulations:</i></p>
<p style="text-indent:0em;margin-left:2em;">IM, short-acting, and IV: Sedation; vital signs (BP, pulse, respiratory rate); ECG (in patients at risk for QT prolongation) (Cole 2017; Taylor 2017).</p>
<p style="text-indent:0em;margin-left:2em;">IM, extended release: Sedation/delirium for 3 hours after each dose.</p></div>
<div class="block rer drugH1Div" id="F51739909"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Schizophrenia:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Timing of serum samples: Draw trough just before next dose (Hiemke 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Therapeutic reference range: 20 to 80 ng/mL (SI: 64 to 256 nmol/L) (Hiemke 2018). <b>Note</b>: Dosing should be based on therapeutic response as opposed to serum concentrations, however therapeutic drug monitoring can be used to confirm adherence (APA [Keepers 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Laboratory alert level: 100 ng/mL (SI: 320 nmol/L) (Hiemke 2018).</p></div>
<div class="block pha drugH1Div" id="F203119"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Olanzapine is a second generation thienobenzodiazepine antipsychotic which displays potent antagonism of serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub>, dopamine D<sub>1-4</sub>, histamine H<sub>1</sub>, and alpha<sub>1</sub>-adrenergic receptors. Olanzapine shows moderate antagonism of 5-HT<sub>3</sub> and muscarinic M<sub>1-5 </sub>receptors, and weak binding to GABA-A, BZD, and beta-adrenergic receptors. Although the precise mechanism of action in schizophrenia and bipolar disorder is not known, the efficacy of olanzapine is thought to be mediated through combined antagonism of dopamine and serotonin type 2 receptor sites. Olanzapine’s activity at the dopamine (D<sub>2</sub>), 5-HT<sub>2C</sub>, and 5-HT<sub>3</sub> receptors may be responsible for the antiemetic effect (Navari 2016).</p></div>
<div class="block phk drugH1Div" id="F203137"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Agitation:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: Initial effects within 15 minutes; continued effects for at least 2 hours (Huang 2015; Wright 2001).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Initial effects within 5 to 10 minutes (Taylor 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Bipolar disorder, acute mania: Oral and IR injection: Oral: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Schizophrenia: Oral: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Well absorbed; not affected by food; tablets and orally disintegrating tablets are bioequivalent</p>
<p style="text-indent:-2em;margin-left:4em;">Short-acting injection: Rapidly absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Extensive, 1,000 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: 93% bound to albumin and alpha<sub>1</sub>-glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Highly metabolized via direct glucuronidation and cytochrome P450 mediated oxidation (CYP1A2, CYP2D6); 40% removed via first pass metabolism</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral and IM (short-acting): Children: (10 to 18 years; n=8): 37.2 ± 5.1 hours (Grothe 2000); Adults: 30 hours [21 to 54 hours (5th to 95th percentile)]; approximately 1.5 times greater in elderly</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release injection: ~30 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Maximum plasma concentrations after IM administration are 5 times higher than maximum plasma concentrations produced by an oral dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release injection: ~7 day</p>
<p style="text-indent:-2em;margin-left:4em;">Short-acting injection: 15 to 45 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Children (10 to 18 years; n=8): 4.7 ± 3.7 hours (Grothe 2000); Adults: ~6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (57%, 7% as unchanged drug); feces (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Children (10 to 18 years; n=8): Apparent: 9.6 ± 2.4 L/hour (Grothe 2000)</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Apparent: 25 L/hour [12 to 47 L/hour (5th to 95th percentile)]; 40% increase in olanzapine clearance in smokers; 30% decrease in females</p></div>
<div class="block phksp drugH1Div" id="F51154907"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The half-life increases 1.5 times.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Clearance is approximately 30% lower in women.</p>
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking: Clearance is approximately 40% higher in smokers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F203142"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Albaxa | Olanole | Olanza | Olanzapine glenmark | Olmed | Rexapin | Zyprexa</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Apsico | Enolex | Midax | Olanzanova | Olanzapina Dosa | Olanzapina rospaw | Olanzapina teva | Onotran | Revertrix | Rolanzax | Sartina | Simina | Tiantrex | Trexol | Zyprexa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aedon | Olanzapin 1a pharma | Olanzapin accord | Olanzapin actavis | Olanzapin Aristo | Olanzapin bluefish | Olanzapin easypharm | Olanzapin G.L. | Olanzapin Genericon | Olanzapin mylan | Olanzapin ranbaxy | Olanzapin ratiopharm | Olanzapin Sandoz | Olanzapin Stada | Olipazix | Zalasta | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo olanzapine | Apotex olanzapine | Aprolan | Aprolan olanzapine | Auro olanzapine | Chemmart olanzapine | Lanzek | Lonza | Lyprosia | Noumed olanzapine | Olancor | Olanza | Olanzaccord | Olanzacor | Olanzapine an | Olanzapine Apotex | Olanzapine arw | Olanzapine as | Olanzapine ch | Olanzapine drla | Olanzapine ga | Olanzapine generichealth | Olanzapine odt generichealth | Olanzapine ps | Olanzapine rbx | Olanzapine Sandoz | Olanzapine Teva | Oprexa | Ozin | Pharmacor olanzapine | Pharmacy choice olanzapine | Prolanza | Pryzex | Stada olanzapine | Terry white chemists olanzapine | Tolaze | Tolazine | Torapine | Torrenia | Zylap | Zylapine | Zypine | Zyprexa | Zyprexa Relprevv | Zyprexa zydis</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Deprex | Lopez | Olanap | Olanor | Oleanz | Pericam | Xytrex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Clingozan | Olanzapin actavis | Olanzapine ab | Olanzapine Apotex | Olanzapine eg | Olanzapine mylan | Olanzapine Ranbaxy | Olanzapine Sandoz | Olanzapine Teva | Zalasta | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alonzap | Bloonis | Egolanza | Lapozan | Lazapix | Nykob | Olanzacon | Olanzapin | Olanzapine gsk | Olanzapine Stada | Olfrex | Parnassan | Zapilux | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Axonium | Crisapina | Expolid | Lanzamed | Neupine | Olancare | Olanexyn | Olanzapina | Olanzapina neo quimica | Olanzys | Olazofren | Onaz | Opinox | Zap | Zesten | Zopina | Zopix | Zyprexa | Zyprexa zydis</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Olanpax | Olanza actavis | Olanzapin actavis | Olanzapin Helvepharm | Olanzapin Mepha | Olanzapin Sandoz | Olanzapin Spirig | Olanzapin spirig hc | Olanzapin zentiva | Zyprexa</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Marvil | Olex | Ranozyp | Zyprexa</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amulsin | Anzap | Olanfar | Olanvitae | Olanzapina | Olanzyl | Oleanz | Olexar | Olivin | Sincris | Zapinex ft | Zyprexa | Zyprexa Zydiz</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao fu ping | Ou Lan Ning | Zyprexa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dozic | Frenial | Meflax | Olanzamax | Olanzamet | Olanzapina | Olanzapina la sante | Olanzapina winthrop | Olanzavitae | Olapina | Olazap | Olex | Oxepine | Prolanz | Prolanz fast | Zap | Zapin | Zelta | Zyprexa | Zyprexa zydis</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aedon | Arkolamyl | Atyzyo | Egolanza | Lapozan | Nykob | Olanzapin actavis | Olanzapin Apotex | Olanzapin bluefish | Olanzapin Egis | Olanzapin mylan | Olanzapin orion | Olanzapin Sandoz | Olanzapin Stada | Olanzapin Teva | Olanzapin zentiva | Olanzapine aurovitas | Olanzapine auxilto | Olanzapine mylan | Olanzapine polpharma | Olanzapine Ranbaxy | Olazax | Olpinat | Parnassan | Stygapon | Zalasta | Zolafren | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Olanzapin | Olanzapin 1a pharma | Olanzapin Aaa | Olanzapin AbZ | Olanzapin actavis | Olanzapin AL | Olanzapin Aristo | Olanzapin Aurobindo | Olanzapin Basics | Olanzapin Beta | Olanzapin biomo | Olanzapin CT | Olanzapin Dexcel | Olanzapin glenmark | Olanzapin hec pharm | Olanzapin Hennig | Olanzapin Heumann | Olanzapin Hexal | Olanzapin Hormosan | Olanzapin mylan | Olanzapin neuraxpharm | Olanzapin pfizer | Olanzapin puren | Olanzapin ratiopharm | Olanzapin Sandoz | Olanzapin Stada | Olanzapin sun | Olanzapin Teva | Olanzapin Winthrop | Olanzapin zentiva | Olanzapine Teva | Zalasta | Zypadhera | Zypadhera e M | Zyprexa</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Enolex | Lanzep | Olanfel | Olansued | Olanzafran | Olanzapina | Olanzapina mamey | Olanzavitae | Olapin | Olazin | Olsar | Olzapin | Panufix | Tiantrex | Unilapin | Zapina | Zyprexa</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Domus | Meflax | Olanzapina la sante | Oleanz | Tanssel | Zyprexa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Farpenta | Kozylex | Lazapix | Olansapiin Nyzol | Olanzapin actavis | Olanzapin Jacobsen | Olanzapin ratiopharm | Olanzapine accord | Olanzapine gsk | Olanzapine orion | Olanzapine Teva | Solazin | Stygapon | Zalasta | Zolafren | Zolaswift | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bioprex | Integrol | Lanzapine | Olanza | Olapex | Olazine | Olazorix | Prexal | Schisolazine | Zyprexa</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arenbil | Arenbil flas | Olanzapina actavis | Olanzapina Aldal | Olanzapina Almus | Olanzapina Alter | Olanzapina Apotex | Olanzapina aurobindo | Olanzapina Bexalabs | Olanzapina bluefish | Olanzapina Cantabria | Olanzapina Cinfa | Olanzapina Combix | Olanzapina flas aristo | Olanzapina flas kern pharma | Olanzapina flas pharma combix | Olanzapina Kern pharma | Olanzapina krka | Olanzapina mabo | Olanzapina mylan | Olanzapina Normon | Olanzapina pensa | Olanzapina pharmagenus | Olanzapina qualigen | Olanzapina ranbaxy | Olanzapina Ratio | Olanzapina Ratiopharm | Olanzapina sandoz | Olanzapina sanovel | Olanzapina stada | Olanzapina tarbis | Olanzapina tarbis farma | Olanzapina tecnige | Olanzapina tecnigen | Olanzapina Tevagen | Olanzapina Vegal | Olanzapina vir | Olanzapina zentiva | Olazax | Zalasta | Zapris | Zolafren | Zypadhera | Zyprexa | Zyprexa velotab</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Olanzapin Aurobindo | Olanzapin Sandoz | Olanzapine Sandoz | Oliza</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Olanzapin actavis | Olanzapin Avansor | Olanzapin bluefish | Olanzapin lilly | Olanzapin orifarm | Olanzapin orion | Olanzapin ratiopharm | Olanzapin Sandoz | Olanzapin Teva | Olanzapine accord | Olanzapine glenmark | Olanzapine mylan | Solazin | Zalasta | Zyprexa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Arkolamyl | Olanzapine accord | Olanzapine actavis | Olanzapine alter | Olanzapine arrow | Olanzapine biogaran | Olanzapine bluefish | Olanzapine cristers | Olanzapine eg | Olanzapine evolugen | Olanzapine Evolupharm | Olanzapine isomed | Olanzapine mylan | Olanzapine pfizer | Olanzapine Ranbaxy | Olanzapine Sandoz | Olanzapine Teva | Olanzapine zentiva | Olanzapine zydus | Onezyp | Zalasta | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Olanzapine accord | Olanzapine Kent | Olanzapine sun | Olanzapine Teva | Zalasta | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bloonis | Caprilon | Fredilan | Lapenza | Lapozan | Lapozan oro | Lazap | Newzypra | Norpen oro | Nyzol | Olansek | Olanzalet | Olanzapine mylan | Olanzapine/glenmark | Olanzapine/Sandoz | Olanzapine/Teva | Olapine | Olastazen | Olenxa | Olmyzem | Ozapex | Villamos | Xoltiva | Zalasta | Zalepin | Zalepin rapid | Zonapin | Zoxil | Zypadhera | Zypefar | Zyprexa</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo olanzapine | Hovid olanzapine | Olanza | Onzapin | Ozapex | Zyprexa</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Olandix | Olanzalux | Olanzapin Cipla | Olanzapin Genera | Olanzapin Krka | Olanzapin PharmaS | Olazin | Vaira | Vaira v | Zalasta | Ziora | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Arkolamyl | Bloonis | Egolanza | Mitab | Olanzapin accord | Olanzapin actavis | Olanzapin bluefish | Olanzapin Egis | Olanzapin lilly | Olanzapin orion | Olanzapin Sandoz | Olanzapin Viketo | Olanzapine actavis | Olanzapine Medana | Olanzapine mylan | Olanzapine Teva | Olanzep | Olazax | Olpinat | Olzin | Parnassan | Zalasta | Zesprone | Zolapin | Zyprexa</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Olandoz | Onzapin | Remital | Sopavel | Zyprexa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Olanzapine actavis | Olanzapine mylan | Olanzapine Teva | Rolyprexa | Zalasta | Zyprexa</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Zappa | Zappa odt | Zyprexa</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aculanz | Anapin rt | Anzip | Cnpinex | Consern | Cypine | Dolpin | Elanza | Jolyon md | Joyzol | Kola | Kolzep | Kolzep mm | Manza | Meltez | Meltolan | Nzipo | O pine | Oanmelt | Olace | Olaford | Olagress | Olan | Olancare | Olandus | Olanex | Olanmat | Olanzotic | Olapax | Olapin | Olarc | Olay | Oleanz | Oleanz rapitab | Oleanz rt | Olet | Olex | Olexa | Olexar | Olez | Olibenz | Olima | Olimelt | Oline | Olinstab | Oliplan | Olisense | Olitabs | Olite | Olixin | Oliza | Olpin | Olpine | Olpine md | Oltha | Olzap | Olzic | Onza | Ooz | Opin | Opticon | Otzup | Ozace | Ozanix | Ozapin md | Ozatex | Ozip | Psycholanz | Psychozap | Tolaz | Tolaz la | Tolaz md | Zepol rd | Zypine</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Olanzasam | Zypraxen</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Kozylex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Arkolamyl | Lazapir | Olafid | Olanzapina accord | Olanzapina actavis | Olanzapina angelini | Olanzapina angenerico | Olanzapina aurobindo | Olanzapina aurobindo pharma italia | Olanzapina bluefish | Olanzapina Doc Generici | Olanzapina EG | Olanzapina Lilly | Olanzapina mylan | Olanzapina pensa | Olanzapina ranbaxy | Olanzapina Reddy | Olanzapina sandoz | Olanzapina Sun | Olanzapina teva | Olanzapina zentiva | Zalasta | Zyprexa</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Benzopain | Olexa | Olzan | Oprexa | Pranza | Prexal | Zylanza | Zyprexa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Zyprexa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Deprex | Lanzine | Olangem | Olapin | Oleanz | Olencip | Opelan | Ozapex | Ozitas | Tolanz | Tolanz ODT | Zepina | Zyprexa | Zyprexa velotab</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A prexa | Bearprexa | Neurozapine | Olanpresor | Olanza | Olanzaod | Olapine | Olzapex | Olzapine | Ozapex | Ozapin | Pms olanzapine | Psyrexa | Sandoz olanzapine | Teva olanzapine | Zyolan | Zypeace | Zyprexa | Zyprexa zydis | Zyrepin | Zyrexa | Zyzapine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Laprix | Olexa | Zyprexa</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo olanzapine | Olanzamed | Olanzax | Olizax | Prexal | Vaincor | Zolapine | Zyprexa | Zyrwan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Egolanza | Kozylex | Lapozan | Lazapix | Olanzapin actavis | Olanzapin ratiopharm | Olanzapine accord | Olanzapine alvogen | Olanzapine Apotex | Olanzapine Medana | Olanzapine orion | Olanzapine polpharma | Olanzapine Ranbaxy | Olanzapine Sandoz | Olanzapine Teva | Olanzapine torrent | Olzin | Solazin | Zalasta | Zolafren | Zolaswift | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Olanzapin ratiophrm | Olanzapine Apotex | Olanzapine eg | Olanzapine instant eg | Olanzapine Sandoz | Zyprexa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Egolanza | Lapozan | Olanzapine accord | Olanzapine actavis | Olanzapine alvogen | Olanzapine aurobindo | Olanzapine orion | Olanzapine Teva | Olazax | Zalasta | Zolafren | Zolaswift | Zyprexa</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lozyxa | Marvil | Medizapin | Medizapine | Nepzan | Olanzapine win | Olynza | Polyzapin | Ranozyp | Xautis | Zyprexa</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acudopik | Acudopik spd | Balerap | Bizos | Bosnov | Efeclon | Eflecon | Fontanivio | Izefrin | Lonopex | Marathon | Marcato | Ohm | Olabis od | Olanzapina | Olaprexa | Olaprexa odt | Oxatech | Sis | Zofrenix | Zyprexa | Zyprexa zydis</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo olanzapine | Olankline tm | Olapine | Oleanz | Olenza | Onzapin | Tolanz ODT | Zyprexa</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Excel charis olanzapine | Lanzep | Olzapin | Opelan | Prexal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Olanzapine accord | Olanzapine actavis | Olanzapine bluefish | Olanzapine centrafarm | Olanzapine focus | Olanzapine glenmark | Olanzapine mylan | Olanzapine navamedic | Olanzapine Sandoz | Olanzapine sun | Olanzapine Teva | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Olanzapin orion | Olanzapin ratiopharm | Olanzapina sandoz | Olanzapine accord | Olanzapine mylan | Olanzapine Teva | Zypadhera | Zyprexa | Zyprexa velotab</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Olanzapine dr reddy | Olanzine | Olanzine d | Zypine | Zyprexa</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Kotico | Medlanz | Olanzavitae | Olapina | Olaprexal | Olazapin | Oleanz | Olzapin | Olzapin ft | Prolexa | Solprex | Zyprexa | Zyprexa zydis</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Epilanz | Epinozal od | Exzapine | Lupilan | Olan | Olandus | Olanfar | Olanpressor | Olavex | Olazin | Oleanz | Olex | Olzadin | Salveo | Stalanza | Supzine | Zanprex | Zapinex | Zeprex | Zonia | Zyprexa</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amprexa | Awalanz | Aziva | Furmium | Jolene | Lepinza | Linzap | Linzapine | Nirvanol | O lanz | O save | Oladay | Olan | Olanzar | Olanzia | Olanzin | Olanzo | Olanzpine | Olaz | Olazap | Olepra | Olimag | Olisa | Olpine | Olsa | Olset | Olzar | Onza | Onze | Onzip | Ozapine | Ozip | Pinaz | Rozapine | Saipin | Schizap | Schizolan | Shizop | Si lenza | Supzine | Zanzia | Zapin | Zapiol | Zapiva | Zasan | Zopera | Zyprexa | Zyripine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anzorin | Egolanza | Lanzapin | Olanzapin actavis | Olanzapin Stada | Olanzapina tzf | Olanzapine +pharma | Olanzapine adamed | Olanzapine Apotex | Olanzapine bluefish | Olanzapine lekam | Olanzapine mylan | Olanzapine Teva | Olanzaran | Olanzin | Olasyn | Olazax | Olpinat | Olzapin | Olzin | Parnassan | Ranofren | Sizin | Synza | Zalasta | Zapilux | Zolafren | Zolafren swift | Zolaxa | Zolaxa rapid | Zopridoxin | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zyprexa | Zyprexa intramuscular</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Olanzapina | Olanzapina Alter | Olanzapina aps | Olanzapina aurobindo | Olanzapina aurovitas | Olanzapina basi | Olanzapina bluefish | Olanzapina ciclum | Olanzapina Cinfa | Olanzapina deka | Olanzapina Genedec | Olanzapina Generis | Olanzapina krka | Olanzapina mylan | Olanzapina Pharmakern | Olanzapina sandoz | Olanzapina teva | Olanzapina tolife | Olanzapina wynn | Zalasta | Zyprexa</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Carex | Dozic | Frenico | Olanzapina bioethic pharma | Olanzapina celsius | Olanzapina eticos | Olanzapina heisecke | Olanzapina prosalud | Olanzapina whelp | Placet | Protil | Zirmapina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Olanza | Olanza ODT | Rexapin Easytab | Zyprexa | Zyprexa Velotab</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aedon | Bloonis | Egolanza | Irropia | Lapozan | Olanzapina actavis | Olanzapina aurobindo | Olanzapina dr. reddy's | Olanzapina lph | Olanzapina medana | Olanzapina polpharma | Olanzapina terapia | Olanzapina teva | Olanzapina torrent | Olanzapine glenmark | Olanzapine gsk | Olazax | Wranelon | Zalasta | Zolaswift | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Egolanza | Normiton | Olanex | Olanzapine canon | Olanzapine Teva | Olanzapine tl | Olanzapine vial | Parnasan | Zalasta | Zalasta Q | Zyprexa | Zyprexa adhera</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo olanzapine | Olana | Olazine | Olenza | Olzapin | Pms-Olanzapine | Pranza | Prexal | Zolan | Zylanza | Zyprexa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Arkolamyl | Olanzapin 2care4 | Olanzapin actavis | Olanzapin bluefish | Olanzapin ebb | Olanzapin lilly | Olanzapin orifarm | Olanzapin orion | Olanzapin ranbaxy | Olanzapin Sandoz | Olanzapin Stada | Olanzapin sun | Olanzapine accord | Olanzapine glenmark | Olanzapine mylan | Olanzapine Teva | Zalasta | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo olanzapine | Olankline | Onzapin | Zyprexa</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bloonis | Olanzapin actavis | Olanzapin Teva | Zapilux | Zolrix | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aedon | Arkolamyl | Bloonis | Lapozan | Nykob | Olanzapin actavis | Olanzapin bluefish | Olanzapin Egis | Olanzapin lilly | Olanzapin mylan | Olanzapin orion | Olanzapin Stada | Olanzapine accord | Olanzapine glenmark | Olanzapine orion | Olanzapine Ranbaxy | Olanzapine Teva | Olazax | Olipazix | Olpinat | Parnassan | Zalasta | Zolafren | Zolaswift | Zypadhera | Zyprexa</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Olanza | Olapin | Zyprexa</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Olanza | Olanzia | Oroza 10 | Oroza 20 | Oroza 5 | Pranza | Vaincor | Zyprexa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Apzet | As pineks | Oferta | Olfrex | Ollafax | Olnegis | Ozaprin | Pinolza | Rexapin | Zolapine | Zophix | Zyprexa | Zyzapin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo olanzapine | Brexa | Lanapine | Nodoff | Okpine | Olan | Olandus | Olipine | Olzapine | Ozapex | Ubixa | Waka olanzapine | Zaprinse | Zypine | Zyprexa</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adagio | Adagio odt | Egolanza | Olacin | Olan | Olfrex | Zalasta | Zolafren | Zyprexa</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Olandus | Olangem | Ozapex | Tolanz ODT</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Domus | Ideanil | Oceanil | Olanzapina | Olpax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fontanivio | Lanzep | Olanzapina | Olanzyl | Olaprex | Stalanza | Xytrex | Zyprexa | Zyprexa zydis</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Olangim | Olanxol | Onegpazin | Zapnex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco olanzapine | Lanazyp | Mylan Olanzapine | Nezolap | Nezolap odt | Olawin | Oleanz | Olexar | Prexolan | Redilanz | Zolanz | Zylena | Zyprexa</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Olex</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Lanzine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Arch Gen Psychiatry</i>. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35582951">
<a name="35582951"></a>Ahmed A, Affleck AG, Angus J, et al; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for the management of adults with delusional infestation 2022. <i>Br J Dermatol.</i> 2022;187(4):472-480. doi:10.1111/bjd.21668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/35582951/pubmed" id="35582951" target="_blank">35582951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18801826">
<a name="18801826"></a>Ahuja N, Palanichamy N, Mackin P, Lloyd A. Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature. <i>J Psychopharmacol</i>. 2010;24(1):125-30. doi:10.1177/0269881108096901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18801826/pubmed" id="18801826" target="_blank">18801826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21961502">
<a name="21961502"></a>Aigner M, Treasure J, Kaye W, Kasper S; WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. <i>World J Biol Psychiatry</i>. 2011;12(6):400-443. doi:10.3109/15622975.2011.602720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21961502/pubmed" id="21961502" target="_blank">21961502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alageel.2016">
<a name="Alageel.2016"></a>Alageel A, Gaffas E. Hematological safety of olanzapine. <i>European Psychiatry</i>. 2016;33:S225. https://www.sciencedirect.com/science/article/abs/pii/S0924933816005605
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31524318">
<a name="31524318"></a>Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a systematic review. <i>Obes Rev</i>. 2019;20(12):1680-1690. doi:10.1111/obr.12934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31524318/pubmed" id="31524318" target="_blank">31524318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003083">
<a name="15003083"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004a;65(2):267-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15003083/pubmed" id="15003083" target="_blank">15003083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747245">
<a name="14747245"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>Diabetes Care</i>. 2004b;27(2):596-601. doi:10.2337/diacare.27.2.596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14747245/pubmed" id="14747245" target="_blank">14747245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2020">
<a name="APA.2020"></a>American Psychiatric Association (APA). <i>Practice Guideline for the Treatment of Patients With Major Depressive Disorder</i>. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed July 16, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861176">
<a name="28861176"></a>Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. <i>World J Diabetes</i>. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28861176/pubmed" id="28861176" target="_blank">28861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30375086">
<a name="30375086"></a>Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. <i>Psychiatry Clin Neurosci</i>. 2019;73(1):27-33. doi:10.1111/pcn.12793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30375086/pubmed" id="30375086" target="_blank">30375086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21426603">
<a name="21426603"></a>Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. <i>Psychol Med</i>. 2011;41(10):2177-2182. doi:10.1017/S0033291711000390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21426603/pubmed" id="21426603" target="_blank">21426603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30654643">
<a name="30654643"></a>Attia E, Steinglass JE, Walsh BT, et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial [published correction appears in <i>Am J Psychiatry</i>. 2019;176(6):489]. <i>Am J Psychiatry</i>. 2019;176(6):449-456. doi:10.1176/appi.ajp.2018.18101125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30654643/pubmed" id="30654643" target="_blank">30654643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15166774">
<a name="15166774"></a>Avella J, Wetli CV, Wilson JC, Katz M, Hahn T. Fatal olanzapine-induced hyperglycemic ketoacidosis. <i>Am J Forensic Med Pathol</i>. 2004;25(2):172-175. doi:10.1097/01.paf.0000127391.85007.f4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15166774/pubmed" id="15166774" target="_blank">15166774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29805808">
<a name="29805808"></a>Balijepalli C, Druyts E, Zoratti MJ, et al. Change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a network meta-analysis. <i>Schizophr Res Treatment</i>. 2018;2018:1543034. doi:10.1155/2018/1543034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29805808/pubmed" id="29805808" target="_blank">29805808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31417404">
<a name="31417404"></a>Barata PC, Santos MJ, Melo JC, Maia T. Olanzapine-induced hyperprolactinemia: two case reports. <i>Front Pharmacol</i>. 2019;10:846. Published 2019 Jul 29. doi:10.3389/fphar.2019.00846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31417404/pubmed" id="31417404" target="_blank">31417404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves. <i>Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385. doi:10.3109/15622975.2013.804195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24379512">
<a name="24379512"></a>Bavle AD, Kumar GM. Olanzapine-induced tardive oculogyric crises. <i>Indian J Psychol Med</i>. 2013;35(4):423-424. doi:10.4103/0253-7176.122249<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24379512/pubmed" id="24379512" target="_blank">24379512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23295003">
<a name="23295003"></a>Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. <i>Psychosomatics</i>. 2013;54(1):1-13. doi:10.1016/j.psym.2012.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23295003/pubmed" id="23295003" target="_blank">23295003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578944">
<a name="25578944"></a>Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. <i>Drugs R D</i>. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25578944/pubmed" id="25578944" target="_blank">25578944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958039">
<a name="19958039"></a>Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. <i>CNS Drugs</i>. 2009;23(12):1003-1021. doi:10.2165/11530020-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19958039/pubmed" id="19958039" target="_blank">19958039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16239162">
<a name="16239162"></a>Biederman J, Mick E, Hammerness P, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. <i>Biol Psychiatry. </i>2005;58(7):589-594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16239162/pubmed" id="16239162" target="_blank">16239162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23983962">
<a name="23983962"></a>Bishop JR, Rubin LH, Reilly JL, Pavuluri MN, Sweeney JA. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. <i>Ther Adv Psychopharmacol</i>. 2012;2(3):95-102. doi:10.1177/2045125312442080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23983962/pubmed" id="23983962" target="_blank">23983962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18558642">
<a name="18558642"></a>Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. <i>Am J Psychiatry</i>. 2008;165(10):1281-1288. doi:10.1176/appi.ajp.2008.07121900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18558642/pubmed" id="18558642" target="_blank">18558642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12804130">
<a name="12804130"></a>Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G. Hyperglycemia from olanzapine treatment in adolescents. <i>J Child Adolesc Psychopharmacol</i>. 2003;13(1):97-102. doi:10.1089/104454603321666234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12804130/pubmed" id="12804130" target="_blank">12804130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12474205">
<a name="12474205"></a>Boachie A, Goldfield GS, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. <i>Int J Eat Disord.</i> 2003;33(1):98-103. doi:10.1002/eat.10115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12474205/pubmed" id="12474205" target="_blank">12474205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12623765">
<a name="12623765"></a>Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. <i>J Sex Marital Ther</i>. 2003;29(2):125-147. doi:10.1080/713847170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12623765/pubmed" id="12623765" target="_blank">12623765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17257085">
<a name="17257085"></a>Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. <i>Expert Opin Pharmacother</i>. 2007;8(2):141-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17257085/pubmed" id="17257085" target="_blank">17257085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12410058">
<a name="12410058"></a>Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. <i>Clin Neuropharmacol</i>. 2002;25(5):263-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12410058/pubmed" id="12410058" target="_blank">12410058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18484558">
<a name="18484558"></a>Bosmans A, Verbanck P. Successful treatment of delusional disorder of the somatic type or "delusional parasitosis" with olanzapine. <i>Pharmacopsychiatry.</i> 2008;41(3):121-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18484558/pubmed" id="18484558" target="_blank">18484558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19113797">
<a name="19113797"></a>Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. <i>Pharmacotherapy</i>. 2009;29(1):64-73. doi:10.1592/phco.29.1.64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19113797/pubmed" id="19113797" target="_blank">19113797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24765884">
<a name="24765884"></a>Brajon D, Trechot P, Waton J, Cuny JF, Schmutz JL, Barbaud A. Suspicion of a new cross-reaction between carbamazepine and olanzapine. <i>J Investig Allergol Clin Immunol</i>. 2014;24(1):60-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24765884/pubmed" id="24765884" target="_blank">24765884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16889444">
<a name="16889444"></a>Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. <i>J Clin Psychiatry</i>. 2006;67(7):1025-1033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16889444/pubmed" id="16889444" target="_blank">16889444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23902726">
<a name="23902726"></a>Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. <i>BMC Pharmacol Toxicol</i>. 2013;14:38. doi:10.1186/2050-6511-14-38<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23902726/pubmed" id="23902726" target="_blank">23902726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27807566">
<a name="27807566"></a>Buszek SM, Roy-Chaudhury P, Yadlapalli G. Olanzapine-induced hypertriglyceridemia resulting in necrotizing pancreatitis. <i>ACG Case Rep J</i>. 2016;3(4):e104. doi:10.14309/crj.2016.77<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27807566/pubmed" id="27807566" target="_blank">27807566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24253372">
<a name="24253372"></a>Butwicka A, Krystyna S, Retka W, Wolańczyk T. Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.<i> Eur J Pediatr</i>. 2014;173(12):1639-1642. doi:10.1007/s00431-013-2208-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24253372/pubmed" id="24253372" target="_blank">24253372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19364288">
<a name="19364288"></a>Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. <i>J Child Adolesc Psychopharmacol</i>. 2009;19(2):101-109. doi:10.1089/cap.2008.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19364288/pubmed" id="19364288" target="_blank">19364288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20331935">
<a name="20331935"></a>Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. <i>J Clin Psychiatry</i>. 2010;71(3):338-347. doi:10.4088/JCP.08m04595gre<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20331935/pubmed" id="20331935" target="_blank">20331935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10718830">
<a name="10718830"></a>Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clin Endocrinol (Oxf)</i>. 2000;52(3):319-327. doi:10.1046/j.1365-2265.2000.00902.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10718830/pubmed" id="10718830" target="_blank">10718830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10511917">
<a name="10511917"></a>Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. <i>Clin Pharmacokinet</i>. 1999;37(3):177-193. doi:10.2165/00003088-199937030-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10511917/pubmed" id="10511917" target="_blank">10511917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30543832">
<a name="30543832"></a>Campbell EH, Elston DM, Hawthorne JD, Beckert DR. Diagnosis and management of delusional parasitosis.<i> J Am Acad Dermatol</i>. 2019;80(5):1428-1434. doi:10.1016/j.jaad.2018.12.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30543832/pubmed" id="30543832" target="_blank">30543832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16529334">
<a name="16529334"></a>Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16529334/pubmed" id="16529334" target="_blank">16529334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146614">
<a name="28146614"></a>Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. <i>J Clin Psychiatry</i>. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28146614/pubmed" id="28146614" target="_blank">28146614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12927004">
<a name="12927004"></a>Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. <i>J Clin Psychiatry</i>. 2003;64(8):898-906. doi:10.4088/jcp.v64n0807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12927004/pubmed" id="12927004" target="_blank">12927004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-148, viii. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15150680">
<a name="15150680"></a>Carrillo JA, González JA, Gervasini G, López R, Fernández MA, Núñez GM. Thrombocytopenia and fatality associated with olanzapine. <i>Eur J Clin Pharmacol</i>. 2004;60(4):295-6. doi:10.1007/s00228-004-0772-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15150680/pubmed" id="15150680" target="_blank">15150680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151456">
<a name="15151456"></a>Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>J Clin Psychiatry</i>. 2004;65(suppl 7):4-18; quiz 19-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15151456/pubmed" id="15151456" target="_blank">15151456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22981685">
<a name="22981685"></a>Chan EW, Taylor DM, Knott JC, Phillips GA, Castle DJ, Kong DC. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. <i>Ann Emerg Med.</i> 2013;61(1):72-81. doi:10.1016/j.annemergmed.2012.07.118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22981685/pubmed" id="22981685" target="_blank">22981685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28852258">
<a name="28852258"></a>Chawla N, Kumar S, Balhara YPS. Olanzapine-induced skin eruptions. <i>Indian J Psychol Med</i>. 2017;39(4):537-538. doi:10.4103/0253-7176.211763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28852258/pubmed" id="28852258" target="_blank">28852258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10831017">
<a name="10831017"></a>Chengappa KN, Pollock BG, Parepally H, et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. <i>J Clin Psychopharmacol</i>. 2000;20(3):311-316. doi:10.1097/00004714-200006000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10831017/pubmed" id="10831017" target="_blank">10831017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16928430">
<a name="16928430"></a>Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. <i>Schizophr Res</i>. 2006;88(1-3):63-72. doi:10.1016/j.schres.2006.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16928430/pubmed" id="16928430" target="_blank">16928430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20394794">
<a name="20394794"></a>Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2010;34(6):866-870. doi:10.1016/j.pnpbp.2010.04.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20394794/pubmed" id="20394794" target="_blank">20394794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27855291">
<a name="27855291"></a>Chou RH, Lo LW, Liou YJ, et al. Antipsychotic treatment is associated with risk of atrial fibrillation: A nationwide nested case-control study. <i>Int J Cardiol</i>. 2017;227:134-140. doi:10.1016/j.ijcard.2016.11.185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27855291/pubmed" id="27855291" target="_blank">27855291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25298577">
<a name="25298577"></a>Choure BK, Gosavi D, Nanotkar S. Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study. <i>Indian J Pharmacol</i>. 2014;46(5):493-497. doi:10.4103/0253-7613.140579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25298577/pubmed" id="25298577" target="_blank">25298577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16696448">
<a name="16696448"></a>Christen S, Gueissaz F, Anex R, Zullino DF. Acute generalized exanthematous pustulosis induced by olanzapine. <i>Acta Medica (Hradec Kralove)</i>. 2006;49(1):75-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16696448/pubmed" id="16696448" target="_blank">16696448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28141623">
<a name="28141623"></a>Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: Absolute risk increase and number needed to harm. <i>J Clin Psychopharmacol</i>. 2017;37(2):138-147. doi:10.1097/JCP.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28141623/pubmed" id="28141623" target="_blank">28141623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21495734">
<a name="21495734"></a>Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. <i>Clin Drug Investig</i>. 2011;31(7):455-482. doi:10.2165/11589060-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21495734/pubmed" id="21495734" target="_blank">21495734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19589053">
<a name="19589053"></a>Citrome L, Kantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? <i>Expert Rev Neurother</i>. 2009;9(7):1045-1058. doi:10.1586/ern.09.54<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19589053/pubmed" id="19589053" target="_blank">19589053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28697164">
<a name="28697164"></a>Cole JB, Klein LR, Strobel AM, Blanchard SR, Nahum R, Martel ML. The use, safety, and efficacy of olanzapine in a level I pediatric trauma center emergency department over a 10-year period. <i>Pediatr Emerg Care</i>. 2020;36(2):70-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28697164/pubmed" id="28697164" target="_blank">28697164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27823873">
<a name="27823873"></a>Cole JB, Moore JC, Dolan BJ, et al. A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department. <i>Ann Emerg Med.</i> 2017;69(3):327-336. doi:10.1016/j.annemergmed.2016.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27823873/pubmed" id="27823873" target="_blank">27823873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19861668">
<a name="19861668"></a>Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. <i>JAMA</i>. 2009;302(16):1765-1773. doi:10.1001/jama.2009.1549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19861668/pubmed" id="19861668" target="_blank">19861668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18533766">
<a name="18533766"></a>Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>J Clin Psychiatry</i>. 2008;69(suppl 4):26-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18533766/pubmed" id="18533766" target="_blank">18533766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32021688">
<a name="32021688"></a>Couturier J, Isserlin L, Norris M, et al. Canadian practice guidelines for the treatment of children and adolescents with eating disorders. <i>J Eat Disord</i>. 2020;8:4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/32021688/pubmed" id="32021688" target="_blank">32021688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: A case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11305706">
<a name="11305706"></a>Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. <i>J Clin Psychiatry</i>. 2001;62(3):191-8. doi:10.4088/jcp.v62n0310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11305706/pubmed" id="11305706" target="_blank">11305706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28049388">
<a name="28049388"></a>D'Angelo RG, Rincavage M, Tata AL, et al. Impact of an antipsychotic discontinuation bundle during transitions of care in critically ill patients. <i>J Intensive Care Med</i>. 2019;34(1):40-47. doi:10.1177/0885066616686741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28049388/pubmed" id="28049388" target="_blank">28049388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29637530">
<a name="29637530"></a>Damkier P, Videbech P. The safety of second-generation antipsychotics during pregnancy: a clinically focused review. <i>CNS Drugs</i>. 2018;32(4):351-366. doi:10.1007/s40263-018-0517-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29637530/pubmed" id="29637530" target="_blank">29637530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34398289">
<a name="34398289"></a>Davis M, Hui D, Davies A, et al. MASCC antiemetics in advanced cancer updated guideline. <i>Support Care Cancer.</i> 2021a;29(12):8097-8107. doi:10.1007/s00520-021-06437-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/34398289/pubmed" id="34398289" target="_blank">34398289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34390398">
<a name="34390398"></a>Davis M, Hui D, Davies A, et al. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. <i>Support Care Cancer.</i> 2021b;29(12):8089-8096. doi:10.1007/s00520-021-06438-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/34390398/pubmed" id="34390398" target="_blank">34390398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14758577">
<a name="14758577"></a>De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. <i>Int J Geriatr Psychiatry</i>. 2004;19(2):115-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14758577/pubmed" id="14758577" target="_blank">14758577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011;8(2):114-126. doi:10.1038/nrendo.2011.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17346932">
<a name="17346932"></a>de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. <i>Schizophr Res</i>. 2007;92(1-3):95-102. doi:10.1016/j.schres.2007.01.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17346932/pubmed" id="17346932" target="_blank">17346932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12702892">
<a name="12702892"></a>Dennehy EB, Doyle K, Suppes T. The efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient setting.<i> Int Clin Psychopharmacol</i>. 2003;18(3):143-145. doi:10.1097/01.yic.0000062801.74434.25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12702892/pubmed" id="12702892" target="_blank">12702892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20537128">
<a name="20537128"></a>Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. <i>BMC Psychiatry</i>. 2010;10:43. doi:10.1186/1471-244X-10-43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20537128/pubmed" id="20537128" target="_blank">20537128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590213">
<a name="25590213"></a>Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2015;100(2):363-370. doi:10.1210/jc.2014-3421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25590213/pubmed" id="25590213" target="_blank">25590213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11054978">
<a name="11054978"></a>Doucette DE, Grenier JP, Robertson PS. Olanzapine-induced acute pancreatitis. <i>Ann Pharmacother</i>. 2000;34(10):1128-1131. doi:10.1345/aph.19390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11054978/pubmed" id="11054978" target="_blank">11054978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27825323">
<a name="27825323"></a>Druyts E, Zoratti MJ, Toor K, et al. Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review. <i>BMC Pediatr</i>. 2016;16(1):181. doi:10.1186/s12887-016-0710-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27825323/pubmed" id="27825323" target="_blank">27825323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DSouza.2020">
<a name="DSouza.2020"></a>D’Souza RS, Hooten WM. Extrapyramidal symptoms. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Published January 2010. Updated August 23, 2020. <a href="https://www.ncbi.nlm.nih.gov/books/NBK534115/?report=printable" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK534115/?report=printable</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16089244">
<a name="16089244"></a>Duggal MK, Singh A, Arunabh, Lolis JD, Guzik HJ. Olanzapine-induced vasculitis. <i>Am J Geriatr Pharmacother</i>. 2005;3(1):21-24. doi:10.1016/j.amjopharm.2005.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16089244/pubmed" id="16089244" target="_blank">16089244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17190846">
<a name="17190846"></a>Dunican KC, DelDotto D. The role of olanzapine in the treatment of anorexia nervosa. <i>Ann Pharmacother.</i> 2007;41(1):111-115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17190846/pubmed" id="17190846" target="_blank">17190846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23278567">
<a name="23278567"></a>Ely SF, Neitzel AR, Gill JR. Fatal diabetic ketoacidosis and antipsychotic medication. <i>J Forensic Sci</i>. 2013;58(2):398-403. doi:10.1111/1556-4029.12044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23278567/pubmed" id="23278567" target="_blank">23278567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414689">
<a name="17414689"></a>Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. <i>J Psychiatr Pract</i>. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17414689/pubmed" id="17414689" target="_blank">17414689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30936333">
<a name="30936333"></a>Farag M, Goad J, Temelcos C. Intractable acute ischaemic priapism occurring secondary to newly commenced olanzapine. <i>BMJ Case Rep</i>. 2019;12(3):e227466. doi:10.1136/bcr-2018-227466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30936333/pubmed" id="30936333" target="_blank">30936333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDASafety.2016">
<a name="FDASafety.2016"></a>FDA drug safety communication: FDA warns about rare but serious skin reactions with mental health drug olanzapine (<i>Zyprexa</i>, <i>Zyprexa Zydis</i>, <i>Zyprexa Relprevv</i>, and <i>Symbyax</i>). Published May 10, 2016. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-rare-serious-skin-reactions-mental-health-drug#:~:text=DRESS%20can%20result%20in%20injury,olanzapine%2Dcontaining%20product%20was%20approved" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-rare-serious-skin-reactions-mental-health-drug#:~:text=DRESS%20can%20result%20in%20injury,olanzapine%2Dcontaining%20product%20was%20approved</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDAMedWatch.2013">
<a name="FDAMedWatch.2013"></a>FDA MedWatch Safety Information and Adverse Event Reporting Program. Zyprexa Relprevv (olanzapine pamoate): Drug Safety Communication - FDA investigating two deaths following injection. <a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm357601.htm" target="_blank">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm357601.htm</a>. Published June 18, 2013. Accessed May 22, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23(suppl 1):27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26960036">
<a name="26960036"></a>Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. <i>Pediatr Blood Cancer</i>. 2016;63(7):1144-1151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26960036/pubmed" id="26960036" target="_blank">26960036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25145624">
<a name="25145624"></a>Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL. The safety of olanzapine in young children: a systematic review and meta-analysis. <i>Drug Saf</i>. 2014;37(10):791-804. doi:10.1007/s40264-014-0219-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25145624/pubmed" id="25145624" target="_blank">25145624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25328089">
<a name="25328089"></a>Flank J, Thackray J, Nielson D, et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review. <i>Pediatr Blood Cancer</i>. 2015;62(3):496-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25328089/pubmed" id="25328089" target="_blank">25328089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23642462">
<a name="23642462"></a>Flint AJ, Iaboni A, Mulsant BH, Rothschild AJ, Whyte EM, Meyers BS; STOP-PD Study Group. Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):332-336. doi:10.1016/j.jagp.2013.01.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23642462/pubmed" id="23642462" target="_blank">23642462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25581312">
<a name="25581312"></a>Fraser LA, Liu K, Naylor KL, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. <i>JAMA Intern Med</i>. 2015;175(3):450-452. doi:10.1001/jamainternmed.2014.6930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25581312/pubmed" id="25581312" target="_blank">25581312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11642474">
<a name="11642474"></a>Frazier JA, Biederman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. <i>J Child Adolesc Psychopharmacol.</i> 2001;11(3):239-250. doi:10.1089/10445460152595568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11642474/pubmed" id="11642474" target="_blank">11642474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794644">
<a name="18794644"></a>Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. <i>J Clin Psychopharmacol.</i> 2008;28(5):500-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18794644 /pubmed" id="18794644 " target="_blank">18794644 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512491">
<a name="27512491"></a>Frise C, Attwood B, Watkinson P, Mackillop L. Life-threatening ketoacidosis in a pregnant woman with psychotic disorder. <i>Obstet Med</i>. 2016;9(1):46-49. doi:10.1177/1753495X15621153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27512491/pubmed" id="27512491" target="_blank">27512491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24003306">
<a name="24003306"></a>Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. <i>Neuropsychiatr Dis Treat</i>. 2013;9:1145-1157. doi:10.2147/NDT.S41333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24003306/pubmed" id="24003306" target="_blank">24003306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12900304">
<a name="12900304"></a>Gardiner SJ, Kristensen JH, Begg EJ, et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. <i>Am J Psychiatry. </i>2003;160(8):1428-1431. doi:10.1176/appi.ajp.160.8.1428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12900304/pubmed" id="12900304" target="_blank">12900304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24158020">
<a name="24158020"></a>Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. <i>J Clin Psychopharmacol</i>. 2014;34(1):109-123. doi:10.1097/JCP.0b013e3182a6096e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24158020/pubmed" id="24158020" target="_blank">24158020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26912127">
<a name="26912127"></a>Garriga M, Pacchiarotti I, Kasper S, et al. World Federation of Societies of Biological Psychiatry. Assessment and management of agitation in psychiatry: expert consensus. <i>World J Biol Psychiatry</i>. 2016;17(2):86-128. doi:10.3109/15622975.2015.1132007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26912127/pubmed" id="26912127" target="_blank">26912127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30881565">
<a name="30881565"></a>Gerson R, Malas N, Feuer V, Silver GH, Prasad R, Mroczkowski MM. Best practices for evaluation and treatment of agitated children and adolescents (BETA) in the emergency department: consensus statement of the American Association for Emergency Psychiatry. <i>West J Emerg Med</i>. 2019;20(2):409-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30881565/pubmed" id="30881565" target="_blank">30881565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346242">
<a name="30346242"></a>Girard TD, Exline MC, Carson SS, et al; MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in critical illness. <i>N Engl J Med</i>. 2018;379(26):2506-2516. doi:10.1056/NEJMoa1808217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30346242/pubmed" id="30346242" target="_blank">30346242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22841129">
<a name="22841129"></a>Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>Eur Neuropsychopharmacol</i>. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22841129/pubmed" id="22841129" target="_blank">22841129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29983780">
<a name="29983780"></a>Gorup E, Rifel J, Petek Šter M. Anticholinergic burden and most common anticholinergic-acting medicines in older general practice patients. <i>Zdr Varst</i>. 2018;57(3):140-147. doi:10.2478/sjph-2018-0018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29983780/pubmed" id="29983780" target="_blank">29983780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10770461">
<a name="10770461"></a>Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. <i>J Clin Psychopharmacol</i>. 2000;20(2):220-225. doi:10.1097/00004714-200004000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10770461/pubmed" id="10770461" target="_blank">10770461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21911107">
<a name="21911107"></a>Grover S, Kumar V, Chakrabarti S. Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. <i>J Psychosom Res</i>. 2011;71(4):277-281. doi:10.1016/j.jpsychores.2011.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21911107/pubmed" id="21911107" target="_blank">21911107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19347775">
<a name="19347775"></a>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania [published correction appears in <i>World J Biol Psychiatry</i>. 2009;10(3):255]. <i>World J Biol Psychiatry</i>. 2009;10(2):85-116. doi:10.1080/15622970902823202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19347775/pubmed" id="19347775" target="_blank">19347775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20148751">
<a name="20148751"></a>Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. <i>World J Biol Psychiatry</i>. 2010;11(2):81-109. doi:10.3109/15622970903555881<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20148751/pubmed" id="20148751" target="_blank">20148751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21790209">
<a name="21790209"></a>Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. <i>CNS Drugs</i>. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21790209/pubmed" id="21790209" target="_blank">21790209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12109926">
<a name="12109926"></a>Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. <i>Drugs</i>. 2002;62(11):1649-1671. doi: 10.2165/00003495-200262110-00006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12109926/pubmed" id="12109926" target="_blank">12109926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15456328">
<a name="15456328"></a>Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. <i>Drugs</i>. 2004;64(20):2291-2314. doi:10.2165/00003495-200464200-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15456328/pubmed" id="15456328" target="_blank">15456328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11199936">
<a name="11199936"></a>Hägg S, Mjörndal T, Lindqvist L. Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine. <i>J Clin Psychopharmacol</i>. 2001;21(1):113-115. doi:10.1097/00004714-200102000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11199936/pubmed" id="11199936" target="_blank">11199936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14709949">
<a name="14709949"></a>Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. <i>J Clin Psychopharmacol</i>. 2004;24(1):62-69. doi:10.1097/01.jcp.0000104913.75206.62<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14709949/pubmed" id="14709949" target="_blank">14709949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31838011">
<a name="31838011"></a>Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in <i>Lancet Oncol</i>. 2020;21(2):e70]. <i>Lancet Oncol</i>. 2020;21(2):242-249. doi:10.1016/S1470-2045(19)30678-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31838011/pubmed" id="31838011" target="_blank">31838011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25168784">
<a name="25168784"></a>Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. <i>CNS Drugs</i>. 2014;28(10):887-920. doi:10.1007/s40263-014-0196-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25168784/pubmed" id="25168784" target="_blank">25168784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HealthCanada.2016">
<a name="HealthCanada.2016"></a>Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Atypical antipsychotics - assessing the potential risk of sleep apnoea. Health Canada website. Available at: <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html" target="_blank">https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html</a>. Published August 16, 2016. Accessed August 23, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789596">
<a name="23789596"></a>Heller MM, Wong JW, Lee ES, et al. Delusional infestations: clinical presentation, diagnosis and treatment. <i>Int J Dermatol.</i> 2013;52(7):775-783. doi:10.1111/ijd.12067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23789596/pubmed" id="23789596" target="_blank">23789596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20600465">
<a name="20600465"></a>Hergüner S. Excessive masturbation associated with olanzapine in a pediatric case. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2010;34(7):1349-1350. doi:10.1016/j.pnpbp.2010.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20600465/pubmed" id="20600465" target="_blank">20600465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095482">
<a name="29095482"></a>Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. <i>J Am Geriatr Soc</i>. 2017;65(12):2580-2586. doi:10.1111/jgs.15066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29095482/pubmed" id="29095482" target="_blank">29095482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23428782">
<a name="23428782"></a>Hill AL, Sun B, McDonnell DP. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine. <i>Clin Schizophr Relat Psychoses</i>. 2014;7(4):216-222. doi:10.3371/CSRP.HISU.020813<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23428782/pubmed" id="23428782" target="_blank">23428782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18216715">
<a name="18216715"></a>Hilt RJ, Woodward TA. Agitation treatment for pediatric emergency patients. <i>J Am Acad Child Adolesc Psychiatry</i>. 2008;47(2):132-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18216715/pubmed" id="18216715" target="_blank">18216715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17069543">
<a name="17069543"></a>Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. <i>J Child Adolesc Psychopharmacol.</i> 2006;16(5):541-548.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17069543/pubmed" id="17069543" target="_blank">17069543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16633146">
<a name="16633146"></a>Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. <i>J Clin Psychopharmacol</i>. 2006;26(2):167-171. doi:10.1097/01.jcp.0000203194.58087.9a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16633146/pubmed" id="16633146" target="_blank">16633146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. <i>Am J Psychiatry</i>. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924506">
<a name="29924506"></a>Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. <i>J Clin Psychiatry</i>. 2018;79(4):17m11764. doi:10.4088/JCP.17m11764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29924506/pubmed" id="29924506" target="_blank">29924506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25791540">
<a name="25791540"></a>Huang CL, Hwang TJ, Chen YH, et al. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. <i>J Formos Med Assoc</i>. 2015;114(5):438-445. doi:10.1016/j.jfma.2015.01.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25791540/pubmed" id="25791540" target="_blank">25791540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27540849">
<a name="27540849"></a>Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. <i>JAMA Psychiatry</i>. 2016;73(9):938-946. doi:10.1001/jamapsychiatry.2016.1520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27540849/pubmed" id="27540849" target="_blank">27540849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21288069">
<a name="21288069"></a>Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ; WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. <i>World J Biol Psychiatry</i>. 2011;12(1):2-32. doi:10.3109/15622975.2010.538083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21288069/pubmed" id="21288069" target="_blank">21288069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25140533">
<a name="25140533"></a>Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS One</i>. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25140533/pubmed" id="25140533" target="_blank">25140533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18615174">
<a name="18615174"></a>Jafferany M, Lowry J. Case report of olanzapine-associated elevation of serum creatine kinase in a 16-year-old boy with heat stroke. <i>Prim Care Companion J Clin Psychiatry</i>. 2008;10(3):250-252. doi:10.4088/pcc.v10n0312c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18615174/pubmed" id="18615174" target="_blank">18615174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25912545">
<a name="25912545"></a>Jana AK, Praharaj SK, Roy N. Olanzapine-induced orthostatic hypotension. <i>Clin Psychopharmacol Neurosci</i>. 2015;13(1):113-114. doi:10.9758/cpn.2015.13.1.113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25912545/pubmed" id="25912545" target="_blank">25912545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jibson.2019">
<a name="Jibson.2019"></a>Jibson MD. Second-generation antipsychotic medications: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046641">
<a name="12046641"></a>Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. <i>Ann Clin Psychiatry</i>. 2002;14(1):59-64. doi:10.1023/a:1015228112495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12046641/pubmed" id="12046641" target="_blank">12046641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24416588">
<a name="24416588"></a>Jones ME, Campbell G, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: A study with the general practice research database. <i>Cardiovasc Psychiatry Neurol</i>. 2013;2013:647476. doi:10.1155/2013/647476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24416588/pubmed" id="24416588" target="_blank">24416588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3819263">
<a name="3819263"></a>Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. <i>J Am Geriatr Soc</i>. 1987;35(3):248-250. doi:10.1111/j.1532-5415.1987.tb02317.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/3819263/pubmed" id="3819263" target="_blank">3819263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21663423">
<a name="21663423"></a>Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. <i>J Child Adolesc Psychopharmacol</i>. 2011;21(3):207-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21663423/pubmed" id="21663423" target="_blank">21663423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27863115">
<a name="27863115"></a>Kaino K, Kumagai R, Furukawa S, et al. Reversible splenial lesion syndrome with a hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine. <i>J Diabetes Investig</i>. 2017;8(3):392-394. doi:10.1111/jdi.12597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27863115/pubmed" id="27863115" target="_blank">27863115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kales.2012">
<a name="Kales.2012"></a>Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. <i>Am J Psychiatry</i>. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22771132">
<a name="22771132"></a>Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. <i>J Pain Symptom Manage</i>. 2012;44(4):604-607. doi:10.1016/j.jpainsymman.2011.10.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22771132/pubmed" id="22771132" target="_blank">22771132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24294486">
<a name="24294486"></a>Kansagra A, Patel S, Wilcox SR. Prolonged hypothermia due to olanzapine in the setting of renal failure: a case report and review of the literature. <i>Ther Adv Psychopharmacol</i>. 2013;3(6):335-339. doi:10.1177/2045125313490304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24294486/pubmed" id="24294486" target="_blank">24294486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12352267">
<a name="12352267"></a>Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. <i>J Clin Psychopharmacol.</i> 2002;22(5):455-460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12352267/pubmed" id="12352267" target="_blank">12352267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20465623">
<a name="20465623"></a>Kenchaiah BK, Kumar S, Tharyan P. Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients. <i>Int J Dermatol. </i>2010;49(1):95-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20465623/pubmed" id="20465623" target="_blank">20465623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486148">
<a name="27486148"></a>Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments [published correction appears in <i>Can J Psychiatry</i>. 2017;62(5):356]. <i>Can J Psychiatry</i>. 2016;61(9):540-560. doi:10.1177/0706743716659417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27486148/pubmed" id="27486148" target="_blank">27486148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11748787">
<a name="11748787"></a>Kennedy JS, Zagar A, Bymaster F, et al. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. <i>Int J Geriatr Psychiatry</i>. 2001;16(suppl 1):S24-S32. doi:10.1002/1099-1166(200112)16:1+&lt;::aid-gps570&gt;3.0.co;2-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11748787/pubmed" id="11748787" target="_blank">11748787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21487466">
<a name="21487466"></a>Kerr TA, Jonnalagadda S, Prakash C, Azar R. Pancreatitis following olanzapine therapy: A report of three cases. <i>Case Rep Gastroenterol</i>. 2007;1(1):15-20. doi:10.1159/000104222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21487466/pubmed" id="21487466" target="_blank">21487466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17201611">
<a name="17201611"></a>Khan SS, Mican LM. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. <i>J Child Adolesc Psychopharmacol.</i> 2006;16(6):671-677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17201611/pubmed" id="17201611" target="_blank">17201611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30758221">
<a name="30758221"></a>Khorassani F, Saad M. Intravenous olanzapine for the management of agitation: review of the literature. <i>Ann Pharmacother</i>. 2019;53(8):853-859. doi:10.1177/1060028019831634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30758221/pubmed" id="30758221" target="_blank">30758221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23261075">
<a name="23261075"></a>Kimmel RJ, Levy MR. Profound hypertriglyceridemia and weight gain in the first week following initiation of olanzapine: a case report with implications for lipid monitoring guidelines. <i>Psychosomatics</i>. 2013;54(4):392-394. doi:10.1016/j.psym.2012.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23261075/pubmed" id="23261075" target="_blank">23261075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29885904">
<a name="29885904"></a>Klein LR, Driver BE, Miner JR, et al. Intramuscular midazolam, olanzapine, ziprasidone, or haloperidol for treating acute agitation in the emergency department. <i>Ann Emerg Med</i>. 2018;72(4):374-385. doi:10.1016/j.annemergmed.2018.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29885904/pubmed" id="29885904" target="_blank">29885904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766935">
<a name="12766935"></a>Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. <i>Hum Psychopharmacol</i>. 2003;18(4):301-309. doi:10.1002/hup.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12766935/pubmed" id="12766935" target="_blank">12766935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12126218">
<a name="12126218"></a>Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. <i>Pharmacotherapy</i>. 2002;22(7):841-852. doi:10.1592/phco.22.11.841.33629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12126218/pubmed" id="12126218" target="_blank">12126218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14613516">
<a name="14613516"></a>Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG, Christodoulou GN. Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome? <i>Ann Gen Hosp Psychiatry</i>. 2003;2(1):10. doi:10.1186/1475-2832-2-10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14613516/pubmed" id="14613516" target="_blank">14613516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15725966">
<a name="15725966"></a>Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M; Child Psychiatric Workgroup on Bipolar Disorder. Treatment guidelines for children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry.</i> 2005;44(3):213-235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15725966/pubmed" id="15725966" target="_blank">15725966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955388">
<a name="19955388"></a>Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. <i>Schizophr Bull</i>. 2010;36(1):94-103. doi:10.1093/schbul/sbp130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19955388/pubmed" id="19955388" target="_blank">19955388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22372514">
<a name="22372514"></a>Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. <i>J Child Adolesc Psychopharmacol</i>. 2012;22(2):157-165. doi:10.1089/cap.2010.0020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22372514/pubmed" id="22372514" target="_blank">22372514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17651705">
<a name="17651705"></a>Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. <i>Biol Psychiatry</i>. 2008a;63(5):524-529. doi:10.1016/j.biopsych.2007.04.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17651705/pubmed" id="17651705" target="_blank">17651705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759640">
<a name="18759640"></a>Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. <i>J Child Adolesc Psychopharmacol</i>. 2008b;18(4):307-316. doi:10.1089/cap.2007.0089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18759640/pubmed" id="18759640" target="_blank">18759640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942. doi:10.1345/aph.1G130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21058927">
<a name="21058927"></a>Lander M, Bastiampillai T. Neutropenia associated with quetiapine, olanzapine, and aripiprazole. <i>Aust N Z J Psychiatry</i>. 2011;45(1):89. doi:10.3109/00048674.2010.524624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21058927/pubmed" id="21058927" target="_blank">21058927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737244">
<a name="23737244"></a>La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. <i>Pharmacopsychiatry</i>. 2013;46(6):201-208. doi:10.1055/s-0033-1347177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23737244/pubmed" id="23737244" target="_blank">23737244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11465633">
<a name="11465633"></a>Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. <i>Psychopharmacology (Berl)</i>. 2001;156(1):53-57. doi:10.1007/s002130000679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11465633/pubmed" id="11465633" target="_blank">11465633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16166184">
<a name="16166184"></a>Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. <i>J Psychopharmacol</i>. 2005;19(5):473-482. doi:10.1177/0269881105056524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16166184/pubmed" id="16166184" target="_blank">16166184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26503496">
<a name="26503496"></a>Lee CP, Chen PJ, Chang CM. Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. <i>Acta Neuropsychiatr</i>. 2015;27(6):380-385. doi:10.1017/neu.2015.29<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26503496/pubmed" id="26503496" target="_blank">26503496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30312108">
<a name="30312108"></a>Lee ES, Vidal C, Findling RL. A focused review on the treatment of pediatric patients with atypical antipsychotics. <i>J Child Adolesc Psychopharmacol</i>. 2018;28(9):582-605.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30312108/pubmed" id="30312108" target="_blank">30312108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20415608">
<a name="20415608"></a>Leggero C, Masi G, Brunori E, et al. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. <i>J Child Adolesc Psychopharmacol</i>. 2010;20(2):127-133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20415608/pubmed" id="20415608" target="_blank">20415608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. <i>Schizophr</i>
<i>Bull</i>. 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17172913">
<a name="17172913"></a>Lim GC, Chen YF, Liu L, Huang SC, Lin KK, Hsiao CH. Camphor-related self-inflicted keratoconjunctivitis complicating delusions of parasitosis. <i>Cornea.</i> 2006;25(10):1254-1256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17172913/pubmed" id="17172913" target="_blank">17172913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30581543">
<a name="30581543"></a>Lin J. Antipsychotics and rashes. <i>Ment Illn</i>. 2018;10(2):7808. doi:10.4081/mi.2018.7808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30581543/pubmed" id="30581543" target="_blank">30581543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22217947">
<a name="22217947"></a>Lin YH, Chien YL. Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report. <i>J Clin Psychopharmacol</i>. 2012;32(1):132-133. doi:10.1097/JCP.0b013e318240dacf<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22217947/pubmed" id="22217947" target="_blank">22217947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25901778">
<a name="25901778"></a>Lock J, La Via MC; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with eating disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2015;54(5):412-425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25901778/pubmed" id="25901778" target="_blank">25901778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25424243">
<a name="25424243"></a>Luedecke D, Schöttle D, Karow A, Lambert M, Naber D. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. <i>CNS Drugs</i>. 2015;29(1):41-46. doi:10.1007/s40263-014-0216-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25424243/pubmed" id="25424243" target="_blank">25424243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15138897">
<a name="15138897"></a>Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report and literature review. <i>Pharmacopsychiatry</i>. 2004;37(3):134-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15138897/pubmed" id="15138897" target="_blank">15138897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21336229">
<a name="21336229"></a>Madden K, Turkel S, Jacobson J, Epstein D, Moromisato DY. Recurrent delirium after surgery for congenital heart disease in an infant. <i>Pediatr Crit Care Med</i>. 2011;12(6):e413-e415. doi:10.1097/PCC.0b013e31820ac2bf<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21336229/pubmed" id="21336229" target="_blank">21336229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30582126">
<a name="30582126"></a>Malik YK, Sahoo S, Avasthi A. Olanzapine-induced leucopaenia and thrombocytopaenia in an elderly patient: a case report and review of the evidence. <i>Gen Psychiatr</i>. 2018;31(2):e000013. doi:10.1136/gpsych-2018-000013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30582126/pubmed" id="30582126" target="_blank">30582126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11501687">
<a name="11501687"></a>Malone RP, Cater J, Sheikh RM, et al. Olanzapine Versus Haloperidol in Children With Autistic Disorder: An Open Pilot Study. <i>J Am Acad Child Adolesc Psychiatry.</i> 2001;40(8):887-894.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11501687/pubmed" id="11501687" target="_blank">11501687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21127693">
<a name="21127693"></a>Maloney AE, Sikich L. Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. <i>Neuropsychiatr Dis Treat</i>. 2010;6:749-766. doi:10.2147/NDT.S6614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21127693/pubmed" id="21127693" target="_blank">21127693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17017841">
<a name="17017841"></a>Markham-Abedi C, de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report. <i>J Clin Psychiatry</i>. 2006;67(9):1473-1474. doi:10.4088/jcp.v67n0922e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17017841/pubmed" id="17017841" target="_blank">17017841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11808820">
<a name="11808820"></a>Markowitz JS, DeVane CL, Boulton DW, Liston HL, Risch SC. Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. <i>J Clin Pharmacol</i>. 2002;42(1):104-106. doi:10.1177/0091270002042001013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11808820/pubmed" id="11808820" target="_blank">11808820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26818629">
<a name="26818629"></a>Marshall J, Herzig SJ, Howell MD, et al. Antipsychotic utilization in the intensive care unit and in transitions of care. <i>J Crit Care</i>. 2016;33:119-24. doi:10.1016/j.jcrc.2015.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26818629/pubmed" id="26818629" target="_blank">26818629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26720055">
<a name="26720055"></a>Martel ML, Klein LR, Rivard RL, et al. A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department.<i> Acad Emerg Med.</i> 2016;23(1):29-35. doi:10.1111/acem.12842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26720055/pubmed" id="26720055" target="_blank">26720055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25786075">
<a name="25786075"></a>Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. <i>JAMA Psychiatry</i>. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25786075/pubmed" id="25786075" target="_blank">25786075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23972700">
<a name="23972700"></a>McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(9):976-990.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23972700/pubmed" id="23972700" target="_blank">23972700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18928414">
<a name="18928414"></a>McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. <i>J Child Adolesc Psychopharmacol</i>. 2008;18:501-508. doi:10.1089/cap.2007.135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18928414/pubmed" id="18928414" target="_blank">18928414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20537130">
<a name="20537130"></a>McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. <i>BMC Psychiatry</i>. 2010;10:45. doi:10.1186/1471-244X-10-45<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20537130/pubmed" id="20537130" target="_blank">20537130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11927174">
<a name="11927174"></a>Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. <i>Neuropsychopharmacology</i>. 2002;26(4):494-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11927174/pubmed" id="11927174" target="_blank">11927174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11469288">
<a name="11469288"></a>Mehler C, Wewetzer C, Schulze U, et al. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. <i>Eur Child Adolesc Psychiatry.</i> 2001;10(2):151-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11469288/pubmed" id="11469288" target="_blank">11469288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18000964">
<a name="18000964"></a>Mehler-Wex C, Romanos M, Kirchheiner J, et al. Atypical antipsychotics in severe anorexia nervosa in children and adolescents - review and case reports. <i>Eur Eat Disord Rev.</i> 2008;16(2):100-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18000964/pubmed" id="18000964" target="_blank">18000964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22689836">
<a name="22689836"></a>Meraj A, Din AU, Larsen L, Liskow BI. Self inflicted corneal abrasions due to delusional parasitosis. <i>BMJ Case Rep.</i> 2011;2011. doi:10.1136/bcr.04.2011.4106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22689836/pubmed" id="22689836" target="_blank">22689836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11476120">
<a name="11476120"></a>Meyer JM. Novel antipsychotics and severe hyperlipidemia. <i>J Clin Psychopharmacol</i>. 2001;21(4):369-374. doi:10.1097/00004714-200108000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11476120/pubmed" id="11476120" target="_blank">11476120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19652123">
<a name="19652123"></a>Meyers BS, Flint AJ, Rothschild AJ, et al; STOP-PD Group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD) [published correction appears in <i>Arch Gen Psychiatry</i>. 2011;68(6):626]. <i>Arch Gen Psychiatry</i>. 2009;66(8):838-847. doi:10.1001/archgenpsychiatry.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19652123/pubmed" id="19652123" target="_blank">19652123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28811926">
<a name="28811926"></a>Meyers KJ, Upadhyaya HP, Landry JL, et al. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study. <i>BJPsych Open</i>. 2017;3(4):186-192. doi:10.1192/bjpo.bp.116.004382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28811926/pubmed" id="28811926" target="_blank">28811926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19706318">
<a name="19706318"></a>Migliardi G, Spina E, D'Arrigo C, et al. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2009;33(8):1496-1501. doi:10.1016/j.pnpbp.2009.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19706318/pubmed" id="19706318" target="_blank">19706318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16001094">
<a name="16001094"></a>Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. <i>Prim Care Companion J Clin Psychiatry</i>. 2004;6(suppl 2):3-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16001094/pubmed" id="16001094" target="_blank">16001094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16001094">
<a name="16001094"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. Published online July 6, 2020. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16001094/pubmed" id="16001094" target="_blank">16001094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.2020">
<a name="Moore.2020"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102845">
<a name="8102845"></a>Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. <i>Arch Gen Psychiatry</i>. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/8102845/pubmed" id="8102845" target="_blank">8102845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17224707">
<a name="17224707"></a>Morrens M, Wezenberg E, Verkes RJ, Hulstijn W, Ruigt GS, Sabbe BG. Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. <i>J Clin Psychopharmacol</i>. 2007;27(1):15-21. doi:10.1097/jcp.0b013e31802dfff0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17224707/pubmed" id="17224707" target="_blank">17224707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17092964">
<a name="17092964"></a>Morissette P, Hreiche R, Mallet L, Vo D, Knaus EE, Turgeon J. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. <i>J Psychopharmacol</i>. 2007;21(7):735-741. doi:10.1177/0269881106072669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17092964/pubmed" id="17092964" target="_blank">17092964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications. <i>Am Fam Physician</i>. 2010;81(5):617-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15641877">
<a name="15641877"></a>Mulsant BH, Gharabawi GM, Bossie CA, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. <i>J Clin Psychiatry</i>. 2004;65(12):1708-1714. doi:10.4088/jcp.v65n1217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15641877/pubmed" id="15641877" target="_blank">15641877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20048451">
<a name="20048451"></a>Nagaraj AK, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. <i>Indian J Psychiatry</i>. 2009;51(4):265-271. doi:10.4103/0019-5545.58291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20048451/pubmed" id="20048451" target="_blank">20048451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32931400">
<a name="32931400"></a>Naik RD, V S, Singh V, Pillai AS, Dhawan D, Bakhshi S. Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial. <i>J Clin Oncol</i>. 2020;38(32):3785-3793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/32931400/pubmed" id="32931400" target="_blank">32931400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28099349">
<a name="28099349"></a>Nanasawa H, Sako A, Mitsutsuka T, Nonogaki K, Kondo T, Mishima S, Uju Y, Ito T, Enomoto T, Hayakawa T, Yanai H. Development of diabetes mellitus associated with quetiapine: A case series. <i>Medicine (Baltimore)</i>. 2017;96(3):e5900. doi:10.1097/MD.0000000000005900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28099349/pubmed" id="28099349" target="_blank">28099349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline [CG183]. Published September 3, 2014. Updated November 2018. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2010">
<a name="NICE.2010"></a>National Institute for Health and Care Excellence (NICE), National Clinical Guideline Centre. Delirium: Diagnosis, Prevention and Management. National Clinical Practice Guideline Number 103, 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17375339">
<a name="17375339"></a>Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. <i>Support Care Cancer.</i> 2007;15(11):1285-1291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17375339/pubmed" id="17375339" target="_blank">17375339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22024310">
<a name="22024310"></a>Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. <i>J Support Oncol</i>. 2011;9(5):188-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22024310/pubmed" id="22024310" target="_blank">22024310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23314603">
<a name="23314603"></a>Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. <i>Support Care Cancer.</i> 2013;21(6):1655-1663.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23314603/pubmed" id="23314603" target="_blank">23314603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32379269">
<a name="32379269"></a>Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial. <i>JAMA Oncol</i>. 2020;6(6):895-899. doi:10.1001/jamaoncol.2020.1052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/32379269/pubmed" id="32379269" target="_blank">32379269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27410922">
<a name="27410922"></a>Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. <i>N Engl J Med</i>. 2016;375(2):134-142. doi:10.1056/NEJMoa1515725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27410922/pubmed" id="27410922" target="_blank">27410922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.2019">
<a name="Nelson.2019"></a>Nelson C. Unipolar depression in adults: Treatment with second-generation antipsychotics. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998156">
<a name="15998156"></a>Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <i>CNS Drugs</i>. 2005;19(suppl 1):1-93. doi:10.2165/00023210-200519001-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15998156/pubmed" id="15998156" target="_blank">15998156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17671284">
<a name="17671284"></a>Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. <i>Am J Psychiatry.</i> 2007;164(8):1214-1220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17671284/pubmed" id="17671284" target="_blank">17671284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi:10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17460408">
<a name="17460408"></a>Nishimura Y. Photosensitivity might be associated with drug-induced hypersensitivity syndrome. <i>Dermatology</i>. 2007;214(4):338-339. doi:10.1159/000100887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17460408/pubmed" id="17460408" target="_blank">17460408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22533871">
<a name="22533871"></a>Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. <i>J Sex Marital Ther</i>. 2012;38(3):281-301. doi:10.1080/0092623X.2011.606883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22533871/pubmed" id="22533871" target="_blank">22533871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17012695">
<a name="17012695"></a>Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. <i>Am J Psychiatry</i>. 2006;163(10):1821-1825. doi:10.1176/ajp.2006.163.10.1821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17012695/pubmed" id="17012695" target="_blank">17012695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31039482">
<a name="31039482"></a>Oughli H, Lenze EJ, Locke AE, et al. Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. <i>J Psychiatr Res</i>. 2019;114:67-74. doi:10.1016/j.jpsychires.2019.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31039482/pubmed" id="31039482" target="_blank">31039482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27568278">
<a name="27568278"></a>Pacchiarotti I, León-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: focus on bipolar disorder. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1562-1578. doi:10.1016/j.euroneuro.2016.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27568278/pubmed" id="27568278" target="_blank">27568278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12027832">
<a name="12027832"></a>Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. <i>Acta Neurol Scand</i>. 2002;105(6):441-444. doi:10.1034/j.1600-0404.2002.01197.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12027832/pubmed" id="12027832" target="_blank">12027832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28387211">
<a name="28387211"></a>Pang N, Thrichelvam N, Naing KO. Olanzapine-induced pancytopenia: A rare but worrying complication. <i>East Asian Arch Psychiatry</i>. 2017;27(1):35-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28387211/pubmed" id="28387211" target="_blank">28387211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16698917">
<a name="16698917"></a>Papaioannides D, Sinapidis D, Korantzopoulos P, Charalabopoulos K. A case of cutaneous vasculitis associated with olanzapine. <i>Int J Low Extrem Wounds</i>. 2006;5(2):116-117. doi:10.1177/1534734606288411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16698917/pubmed" id="16698917" target="_blank">16698917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11235936">
<a name="11235936"></a>Parris C, Mack JM, Cochiolo JA, Steinmann AF, Tietjen J. Hypothermia in 2 patients treated with atypical antipsychotic medication. <i>J Clin Psychiatry</i>. 2001;62(1):61-63. doi:10.4088/jcp.v62n0112g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11235936/pubmed" id="11235936" target="_blank">11235936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30484239">
<a name="30484239"></a>Pasina L, Colzani L, Cortesi L, et al. Relation between delirium and anticholinergic drug burden in a cohort of hospitalized older patients: An observational study. <i>Drugs Aging</i>. 2019;36(1):85-91. doi:10.1007/s40266-018-0612-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30484239/pubmed" id="30484239" target="_blank">30484239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. <i>BMC Neurol</i>. 2019;19(1):174. Published 2019 Jul 20. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735957">
<a name="9735957"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatr Serv</i>. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/9735957/pubmed" id="9735957" target="_blank">9735957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28784381">
<a name="28784381"></a>Penchilaiya V, Kuppili PP, Preeti K, Bharadwaj B. DRESS syndrome: Addressing the drug hypersensitivity syndrome on combination of sodium valproate and olanzapine. <i>Asian J Psychiatr</i>. 2017;28:175-176. doi:10.1016/j.ajp.2017.05.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28784381/pubmed" id="28784381" target="_blank">28784381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23131886">
<a name="23131886"></a>Pérez-Iglesias R, Mata I, Martínez-García O, et al. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. <i>J Clin Psychopharmacol</i>. 2012;32(6):804-808. doi:10.1097/JCP.0b013e318272688b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23131886/pubmed" id="23131886" target="_blank">23131886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15876904">
<a name="15876904"></a>Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. <i>J Clin Psychopharmacol</i>. 2005;25(3):250-254. doi:10.1097/01.jcp.0000162800.64378.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15876904/pubmed" id="15876904" target="_blank">15876904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24313745">
<a name="24313745"></a>Petersen AB, Andersen SE, Christensen M, Larsen HL. Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care. <i>Clin Toxicol (Phila)</i>. 2014;52(1):39-43. doi:10.3109/15563650.2013.862258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24313745/pubmed" id="24313745" target="_blank">24313745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24677189">
<a name="24677189"></a>Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. <i>CNS Drugs</i>. 2014;28(5):421-453. doi:10.1007/s40263-014-0157-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24677189/pubmed" id="24677189" target="_blank">24677189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26946767">
<a name="26946767"></a>Popović I, Ravanić D, Janković S, et al. Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome. <i>Srp Arh Celok Lek</i>. 2015;143(11-12):712-718. doi:10.2298/sarh1512712p<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26946767/pubmed" id="26946767" target="_blank">26946767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.2019">
<a name="Post.2019"></a>Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22157728">
<a name="22157728"></a>Prevost P, Bédry R, Lacoste D, Ezzedine K, Haramburu F, Milpied B. Hypersensitivity syndrome with olanzapine confirmed by patch tests. <i>Eur J Dermatol</i>. 2012;22(1):126-127. doi:10.1684/ejd.2011.1553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22157728/pubmed" id="22157728" target="_blank">22157728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22397999">
<a name="22397999"></a>Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22397999/pubmed" id="22397999" target="_blank">22397999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31061208">
<a name="31061208"></a>Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i>. 2019;92(19):896-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31061208/pubmed" id="31061208" target="_blank">31061208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21592373">
<a name="21592373"></a>Rasnayake LR, Wimalarathne H, Jayapala RK, et al. An unusual case of hypothermia associated with therapeutic doses of olanzapine: a case report. <i>J Med Case Rep</i>. 2011;5:189. doi:10.1186/1752-1947-5-189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21592373/pubmed" id="21592373" target="_blank">21592373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19144938">
<a name="19144938"></a>Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. <i>N Engl J Med</i>. 2009;360(3):225-235. doi:10.1056/NEJMoa0806994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19144938/pubmed" id="19144938" target="_blank">19144938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11217818">
<a name="11217818"></a>Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. <i>Am J Med Sci</i>. 2001;321(2):156-158. doi:10.1097/00000441-200102000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11217818/pubmed" id="11217818" target="_blank">11217818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29600715">
<a name="29600715"></a>Reddy B, Das S, B U. Olanzapine-induced photo-allergic reaction. <i>Aust N Z J Psychiatry</i>. 2018;52(8):807-808. doi:10.1177/0004867418767558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29600715/pubmed" id="29600715" target="_blank">29600715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi:10.1016/j.schres.2005.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30700054">
<a name="30700054"></a>Resmark G, Herpertz S, Herpertz-Dahlmann B, Zeeck A. Treatment of anorexia nervosa-new evidence-based guidelines. <i>J Clin Med</i>. 2019;8(2):153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30700054/pubmed" id="30700054" target="_blank">30700054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. <i>Am J Psychiatry</i>. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi:10.1176/appi.ajp.2015.173501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10340682">
<a name="10340682"></a>Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;60(suppl 10):5-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10340682/pubmed" id="10340682" target="_blank">10340682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11261526">
<a name="11261526"></a>Roefaro J, Mukherjee SM. Olanzapine-lnduced hyperglycemic nonketonic coma. <i>Ann Pharmacother</i>. 2001;35(3):300-302. doi:10.1345/aph.10178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11261526/pubmed" id="11261526" target="_blank">11261526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24424705">
<a name="24424705"></a>Roffeei SN, Reynolds GP, Zainal NZ, et al. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. <i>Hum Psychopharmacol</i>. 2014;29(1):38-45. doi:10.1002/hup.2366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24424705/pubmed" id="24424705" target="_blank">24424705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26218604">
<a name="26218604"></a>Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. <i>Pharmacol Res</i>. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26218604/pubmed" id="26218604" target="_blank">26218604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19702492">
<a name="19702492"></a>Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. <i>J Child Adolesc Psychopharmacol</i>. 2009;19(4):403-414. doi:10.1089/cap.2008.0120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19702492/pubmed" id="19702492" target="_blank">19702492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20871665">
<a name="20871665"></a>Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. <i>Int J Pediatr Endocrinol</i>. 2010;2010:159402. doi:10.1155/2010/159402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20871665/pubmed" id="20871665" target="_blank">20871665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rothschild.2019">
<a name="Rothschild.2019"></a>Rothschild AJ. Unipolar major depression with psychotic features: Maintenance treatment and course of illness. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12716238">
<a name="12716238"></a>Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication?<i> J Clin Psychiatry</i>. 2003;64(4):390-396. doi:10.4088/jcp.v64n0405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12716238/pubmed" id="12716238" target="_blank">12716238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15232326">
<a name="15232326"></a>Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. <i>J Clin Psychopharmacol</i>. 2004;24(4):365-373. doi:10.1097/01.jcp.0000130557.08996.7a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15232326/pubmed" id="15232326" target="_blank">15232326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roy-Byrne.2019">
<a name="Roy-Byrne.2019"></a>Roy-Byrne PP. Management of psychiatric disorders in patients with cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25879993">
<a name="25879993"></a>Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. <i>BMC Geriatr</i>. 2015;15:31. doi:10.1186/s12877-015-0029-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25879993/pubmed" id="25879993" target="_blank">25879993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31214423">
<a name="31214423"></a>Sassano-Higgins S, Freudenberg N, Jacobson J, Turkel S. Olanzapine reduces delirium symptoms in the critically ill pediatric patient. <i>J Pediatr Intensive Care</i>. 2013;2(2):49-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31214423/pubmed" id="31214423" target="_blank">31214423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17035647">
<a name="17035647"></a>Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. <i>N Engl J Med</i>. 2006;355(15):1525-1538.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17035647/pubmed" id="17035647" target="_blank">17035647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31425493">
<a name="31425493"></a>Schoretsanitis G, Westin AA, Deligiannidis KM, Spigset O, Paulzen M. Excretion of antipsychotics into the amniotic fluid, umbilical cord blood, and breast milk: a systematic critical review and combined analysis [published online August 16, 2019]. <i>Ther Drug Monit</i>. 2019. doi:10.1097/FTD.0000000000000692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31425493/pubmed" id="31425493" target="_blank">31425493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30838312">
<a name="30838312"></a>Schultz JL, Kamholz JA, Nopoulos PC, Killoran A. Comparing risperidone and olanzapine to tetrabenazine for the management of chorea in Huntington disease: an analysis from the Enroll-HD database. <i>Mov Disord Clin Pract</i>. 2018;6(2):132-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30838312/pubmed" id="30838312" target="_blank">30838312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21191308">
<a name="21191308"></a>Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>Int Clin Psychopharmacol</i>. 2011;26(3):130-140. doi:10.1097/YIC.0b013e328341e434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21191308/pubmed" id="21191308" target="_blank">21191308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16818861">
<a name="16818861"></a>Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. <i>Arch Gen Psychiatry.</i> 2006;63(7):721-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16818861/pubmed" id="16818861" target="_blank">16818861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shelton.2019">
<a name="Shelton.2019"></a>Shelton RC, Bobo WV. Bipolar major depression in adults: Choosing treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21645873">
<a name="21645873"></a>Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. <i>Sleep Med</i>. 2011;12(6):591-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21645873/pubmed" id="21645873" target="_blank">21645873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794207">
<a name="18794207"></a>Sikich L, Frazier JA, McClellan J, et al. Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. <i>Am J Psychiatry.</i> 2008;165(11):1420-1431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18794207/pubmed" id="18794207" target="_blank">18794207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24226327">
<a name="24226327"></a>Skomedal T, Hanem S, Dybvik T, Ilner SO. Long-acting injectable olanzapine can give rise to a condition consistent with central anticholinergic syndrome. <i>Tidsskr Nor Laegeforen</i>. 2013;133(21):2238-2239. doi:10.4045/tidsskr.13.0335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24226327/pubmed" id="24226327" target="_blank">24226327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14685663">
<a name="14685663"></a>Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. <i>Intensive Care Med</i>. 2004;30(3):444-449.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14685663/pubmed" id="14685663" target="_blank">14685663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi:10.2147/TCRM.S117321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28845181">
<a name="28845181"></a>Song JM, Jung YE, Park JH, Kim MD, Cheon MS, Lee CI. Neosensitization to multiple drugs following valproate-induced drug reaction with eosinophilia and systemic symptoms syndrome. <i>Psychiatry Investig</i>. 2017;14(4):518-520. doi:10.4306/pi.2017.14.4.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28845181/pubmed" id="28845181" target="_blank">28845181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23343447">
<a name="23343447"></a>Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. <i>Curr Clin Pharmacol</i>. 2014;9(3):310-317. doi:10.2174/15748847113089990051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23343447/pubmed" id="23343447" target="_blank">23343447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28845181">
<a name="28845181"></a>Steinman M, Reeve E. Deprescribing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28845181/pubmed" id="28845181" target="_blank">28845181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21047395">
<a name="21047395"></a>Stauffer VL, Sniadecki JL, Piezer KW, et al. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. <i>BMC Psychiatry</i>. 2010;10:89. doi:10.1186/1471-244X-10-89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21047395/pubmed" id="21047395" target="_blank">21047395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32425825">
<a name="32425825"></a>Stefanou MI, Vittore D, Wolz I, Klingberg S, Wildgruber D. Recurrent Episodes of Paraphilic Behavior Possibly Associated With Olanzapine and Aripiprazole Treatment in a Patient With Schizophrenia. <i>Front Psychiatry</i>. 2020;11:318. doi:10.3389/fpsyt.2020.00318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/32425825/pubmed" id="32425825" target="_blank">32425825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319022">
<a name="15319022"></a>Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study. <i>J Child Adolesc Psychopharmacol</i>. 2004;14(2):255-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15319022/pubmed" id="15319022" target="_blank">15319022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24938920">
<a name="24938920"></a>Stiegler A, Schaletzky R, Walter G, et al. Olanzapine treatment during pregnancy and breastfeeding: a chance for women with psychotic illness? <i>Psychopharmacology (Berl)</i>. 2014;231(15):3067-3069. doi:10.1007/s00213-014-3647-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24938920/pubmed" id="24938920" target="_blank">24938920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16096514">
<a name="16096514"></a>Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. <i>Int Clin Psychopharmacol</i>. 2005;20(5):243-251. doi:10.1097/01.yic.0000166405.49473.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16096514/pubmed" id="16096514" target="_blank">16096514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.2019">
<a name="Stovall.2019"></a>Stovall J. Bipolar mania and hypomania in adults: Choosing pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11015815">
<a name="11015815"></a>Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. <i>Arch Gen Psychiatry</i>. 2000;57(10):968-976.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11015815/pubmed" id="11015815" target="_blank">11015815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suchowersky.2019">
<a name="Suchowersky.2019"></a>Suchowersky O. Huntington disease: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suh.2019">
<a name="Suh.2019"></a>Suh KN. Treatment of delusional infestation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 1, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18519523">
<a name="18519523"></a>Sultzer DL, Davis SM, Tariot PN, et al; CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. <i>Am J Psychiatry</i>. 2008;165(7):844-854. doi:10.1176/appi.ajp.2008.07111779<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18519523/pubmed" id="18519523" target="_blank">18519523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30246876">
<a name="30246876"></a>Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. <i>Cochrane Database Syst Rev</i>. 2018;9:CD012555. doi:10.1002/14651858.CD012555.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30246876/pubmed" id="30246876" target="_blank">30246876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21823168">
<a name="21823168"></a>Suzuki Y, Ono S, Sugai T, et al. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. <i>Hum Psychopharmacol</i>. 2011;26(6):440-443. doi:10.1002/hup.1218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21823168/pubmed" id="21823168" target="_blank">21823168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30398998">
<a name="30398998"></a>Szota AM, Araszkiewicz AS. The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors. <i>Int Clin Psychopharmacol</i>. 2019;34(1):1-8. doi:10.1097/YIC.0000000000000244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30398998/pubmed" id="30398998" target="_blank">30398998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull</i>. 2017;43(4):862-871. doi:10.1093/schbul/sbw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27745766">
<a name="27745766"></a>Taylor DM, Yap CY, Knott JC, et al. Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial.<i> Ann Emerg Med.</i> 2017;69(3):318-326. doi:10.1016/j.annemergmed.2016.07.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27745766/pubmed" id="27745766" target="_blank">27745766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tietze.2020">
<a name="Tietze.2020"></a>Tietze K, Fuchs B. Sedative-analgesic medications in critically ill adults: Properties, dose regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152 Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651 Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(6):981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11249804">
<a name="11249804"></a>Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disord</i>. 2000;2(3 Pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11249804/pubmed" id="11249804" target="_blank">11249804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17898346">
<a name="17898346"></a>Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania. <i>Am J Psychiatry</i>. 2007;164(10):1547-1556.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17898346/pubmed" id="17898346" target="_blank">17898346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22918966">
<a name="22918966"></a>Tohen M, McDonnell DP, Case M, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. <i>Br J Psychiatry</i>. 2012;201(5):376-382. doi:10.1192/bjp.bp.112.108357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22918966/pubmed" id="22918966" target="_blank">22918966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14609883">
<a name="14609883"></a>Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published correction appears in <i>Arch Gen Psychiatry</i>. 2004;61(2):176]. <i>Arch Gen Psychiatry</i>. 2003;60(11):1079-1088.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14609883/pubmed" id="14609883" target="_blank">14609883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11817522">
<a name="11817522"></a>Tolosa-Vilella C, Ruiz-Ripoll A, Mari-Alfonso B, Naval-Sendra E. Olanzapine-induced agranulocytosis: a case report and review of the literature. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2002;26(2):411-414. doi 10.1016/s0278-5846(01)00258-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11817522/pubmed" id="11817522" target="_blank">11817522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22626633">
<a name="22626633"></a>Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. <i>Br J Psychiatry</i>. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22626633/pubmed" id="22626633" target="_blank">22626633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24595134">
<a name="24595134"></a>Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. <i>BMJ Open</i>. 2014;4(3):e004216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24595134/pubmed" id="24595134" target="_blank">24595134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24898718">
<a name="24898718"></a>Turkel SB, Hanft A. The pharmacologic management of delirium in children and adolescents. <i>Paediatr Drugs</i>. 2014;16(4):267-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24898718/pubmed" id="24898718" target="_blank">24898718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22364403">
<a name="22364403"></a>Turkel SB, Jacobson J, Munzig E, Tavaré CJ. Atypical antipsychotic medications to control symptoms of delirium in children and adolescents. <i>J Child Adolesc Psychopharmacol</i>. 2012;22(2):126-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22364403/pubmed" id="22364403" target="_blank">22364403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23782129">
<a name="23782129"></a>Turkel SB, Jacobson JR, Tavaré CJ. The diagnosis and management of delirium in infancy. <i>J Child Adolesc Psychopharmacol</i>. 2013;23(5):352-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23782129/pubmed" id="23782129" target="_blank">23782129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27028982">
<a name="27028982"></a>Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. <i>J Clin Psychopharmacol</i>. 2016;36(3):244-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27028982/pubmed" id="27028982" target="_blank">27028982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30598964">
<a name="30598964"></a>Uvais NA, Sreeraj VS. Seizure associated with olanzapine. J Family Med Prim Care. 2018 Sep-Oct;7(5):1090-1092. doi:10.4103/jfmpc.jfmpc_405_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30598964/pubmed" id="30598964" target="_blank">30598964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31342625">
<a name="31342625"></a>Valladales-Restrepo LF, Duran-Lengua M, Machado-Alba JE. Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer's disease patients. <i>Geriatr Gerontol Int</i>. 2019;19(9):913-917. doi:10.1111/ggi.13748<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31342625/pubmed" id="31342625" target="_blank">31342625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19264412">
<a name="19264412"></a>van Bruggen M, van Amelsvoort T, Wouters L, Dingemans P, de Haan L, Linszen D. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. <i>Psychoneuroendocrinology</i>. 2009;34(7):989-995. doi:10.1016/j.psyneuen.2009.01.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19264412/pubmed" id="19264412" target="_blank">19264412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401555">
<a name="17401555"></a>van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. <i>Eur J Clin Pharmacol</i>. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17401555/pubmed" id="17401555" target="_blank">17401555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18348593">
<a name="18348593"></a>van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. <i>J Clin Psychiatry</i>. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18348593/pubmed" id="18348593" target="_blank">18348593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30747749">
<a name="30747749"></a>Venkatesan V, Khanra S, Mandal K, Deepak MB. Postinjection delirium/sedation syndrome after 31st long-acting olanzapine depot injection. <i>Clin Neuropharmacol</i>. 2019;42(2):64-65. doi:10.1097/WNF.0000000000000329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/30747749/pubmed" id="30747749" target="_blank">30747749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16244481">
<a name="16244481"></a>Verhey FR, Verkaaik M, Lousberg R; Olanzapine-Haloperidol in Dementia Study Group. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. <i>Dement Geriatr Cogn Disord</i>. 2006;21(1):1-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16244481/pubmed" id="16244481" target="_blank">16244481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Walsh.2019">
<a name="Walsh.2019"></a>Walsh BT. Anorexia nervosa in adults: Pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24481570">
<a name="24481570"></a>Wang M, Tong JH, Huang DS, Zhu G, Liang GM, Du H. Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study. <i>Psychopharmacology (Berl)</i>. 2014;231(14):2811-2818. doi:10.1007/s00213-014-3453-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24481570/pubmed" id="24481570" target="_blank">24481570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27780320">
<a name="27780320"></a>Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27780320/pubmed" id="27780320" target="_blank">27780320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114630">
<a name="22114630"></a>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. <i>Dtsch Arztebl Int</i>. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22114630/pubmed" id="22114630" target="_blank">22114630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28643331">
<a name="28643331"></a>Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Treatment with antipsychotics in pregnancy: changes in drug disposition. <i>Clin Pharmacol The</i>r. 2018;103(3):477-484. doi:10.1002/cpt.770<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28643331/pubmed" id="28643331" target="_blank">28643331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18801835">
<a name="18801835"></a>Whitworth A, Stuppaeck C, Yazdi K, et al. Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months. <i>J Psychopharmacol</i>. 2010;24(1):121-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18801835/pubmed" id="18801835" target="_blank">18801835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19880189">
<a name="19880189"></a>Wijkstra J, Burger H, van den Broek WW, et al. Long-term response to successful acute pharmacological treatment of psychotic depression.<i> J Affect Disord</i>. 2010;123(1-3):238-242. doi:10.1016/j.jad.2009.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19880189/pubmed" id="19880189" target="_blank">19880189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21601409">
<a name="21601409"></a>Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. <i>J Emerg Med</i>. 2012a;43(5):790-797. doi:10.1016/j.jemermed.2011.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21601409/pubmed" id="21601409" target="_blank">21601409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461918">
<a name="22461918"></a>Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. <i>West J Emerg Med</i>. 2012b;13(1):26-34. doi:10.5811/westjem.2011.9.6866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22461918/pubmed" id="22461918" target="_blank">22461918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21508932">
<a name="21508932"></a>Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. <i>Neuropsychopharmacology</i>. 2011;36(8):1738-1746. doi:10.1038/npp.2011.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21508932/pubmed" id="21508932" target="_blank">21508932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31570648">
<a name="31570648"></a>Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2019;144(4):e20192528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/31570648/pubmed" id="31570648" target="_blank">31570648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12447030">
<a name="12447030"></a>Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-associated adverse events. <i>J Am Acad Child Adolesc Psychiatry</i>. 2002;41(12):1439-1446. doi:10.1097/00004583-200212000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12447030/pubmed" id="12447030" target="_blank">12447030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19877978">
<a name="19877978"></a>Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. <i>J Child Adolesc Psychopharmacol.</i> 2009;19(5):539-545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19877978/pubmed" id="19877978" target="_blank">19877978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11431240">
<a name="11431240"></a>Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. <i>Am J Psychiatry</i>. 2001;158(7):1149-1151. doi:10.1176/appi.ajp.158.7.1149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11431240/pubmed" id="11431240" target="_blank">11431240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497507">
<a name="25497507"></a>Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. <i>Psychosomatics</i>. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/25497507/pubmed" id="25497507" target="_blank">25497507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi:10.1111/bdi.12609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28936184">
<a name="28936184"></a>Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: A systematic review. <i>Front Psychiatry</i>. 2017;8:165. doi:10.3389/fpsyt.2017.00165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/28936184/pubmed" id="28936184" target="_blank">28936184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zyprexa.2020.04">
<a name="Zyprexa.2020.04"></a>Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ZyprexaRelprevv.2020.04">
<a name="ZyprexaRelprevv.2020.04"></a>Zyprexa Relprevv (olanzapine) [prescribing information]. Indianapolis; IN: Lilly USA LLC; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ZyprexaZydis.2020.04">
<a name="ZyprexaZydis.2020.04"></a>Zyprexa, Zyprexa Zydis, Zyprexa IntraMuscular (olanzapine) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; April 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9716 Version 668.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
